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HIV-1	 is	 a	 pathogenic	 retrovirus,	 which	 often	 develops	 into	 acquired	 immune	
deficiency	syndrome	(AIDS)	and	inevitably	leads	to	death.	The	virus	has	directly	
caused	 an	 estimated	 36	 million	 deaths	 worldwide,	 and	 is	 the	 second	 highest	
attributed	 contributor	 to	 deaths	 caused	 by	 communicable	 diseases.	 This	 high	
mortality	rate	is	due	to	the	virus’	ability	to	evade	treatment	regimes	by	having	an	
incredibly	 high	 rate	 of	 genomic	 mutation.	 However	 a	 highly	 conserved	
mechanism	 has	 been	 discovered	 that	 exhibits	 a	 novel	 control	 of	 protein	
expression.	 The	 -1	 programmed	 ribosomal	 frameshifting	 region	 (-1PRF)	 is	
located	 between	 the	 gag	 and	 pol	 coding	 regions	 of	 the	 HIV-1	 genome.	 By	
developing	 a	mechanism	 that	 allows	 shifting	 between	 frames,	 HIV-1	 has	 been	
able	to	condense	its	genome	and	tightly	control	expression	of	the	Gag-Pol	protein	
products.		
The	 PRF	 element	 is	 made	 up	 of	 three	 sub-elements,	 known	 as	 the	 slippery	
sequence,	intercodon	and	secondary	structural	element	(SSE).	Although	previous	
studies	have	hypothesised	 the	 importance	of	 each	 sub-element,	 the	 interaction	
and	 causative	 effect	 was	 unknown.	 Substitution	 of	 the	 SSEs	 of	 HIV-1	 and	
Paternally	 Expressed	 Gene	 10	 (PEG10)	 showed	 that	 the	 much	 larger	 PEG10	
pseudoknot	 increased	the	efficiency	of	 frameshifting	in	HIV-1	by	60%,	whereas	
the	contrasting	substitution	dropped	PEG10	efficiency	down	95%.	This	indicates	
that	 PEG10	 relies	 heavily	 on	 the	 SSE	 to	 produce	 its	 high	 native	 frameshift	
efficiency.	 Substitution	 of	 the	 intercodon	 revealed	 a	 degree	 of	 ribosomal	
sampling	in	HIV-1	as	a	small	increase	was	observed,	however	no	variation	in	the	
PEG10	construct	implied	that	no	such	sampling	occurs	in	this	mechanism.	
Due	 to	 the	 mechanism’s	 highly	 conserved	 nature,	 it	 is	 the	 ideal	 candidate	 for	
RNA	targeting	molecules.	The	Tate	laboratory	previously	discovered	three	small	
molecule	 modulatory	 compounds,	 which	 were	 shown	 to	 affect	 HIV-1	
frameshifting	efficiency.	However	as	 there	are	 several	known	retrotransposon-
derived	 elements	 within	 mammals,	 there	 was	 a	 possibility	 of	 interaction	
between	 the	 compound	 and	 human	 -1PRF	 mechanisms.	 When	 exposed	 to	 a	
range	of	 concentrations	up	 to	20μM	of	 compound	A3,	 CCR5	exhibited	minimal	
increases,	similar	 to	 those	seen	 in	PEG10	and	 far	below	the	 interaction	seen	 in	
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-1PRF	 	 	 -1	Programmed	Ribosomal	Frameshifting	
AIDS	 	 	 Acquired	Immune	Deficiency	Syndrome	
A	site	 	 	 Amino	Acid	Site	
ATP	 	 	 Adenosine-5’-triphosphate	
ATPase	 	 Adenosine-5’-triphosphatase	
att	site	 	 Attachment	Site	
AZT	 	 	 Azidothymidine	
BLAST		 	 Basic	Local	Alignment	Search	Tool	
CA	 	 	 Capsid	Protein	
CCR5	 	 	 C-C	Chemokine	Receptor	Type	5	
Cdk9	 	 	 Cyclin	Dependent	Kinase	9	
CHMP	 	 	 Charged	Multivesicular	Body	Protein	
CHR	 	 	 C-terminal	Heptad	Repeat	
Crm1	 	 	 Chromosomal	Maintenance	I	
C-terminal	 	 Carboxyl-terminal	
cryo-EM	 	 Cryoelectron	Microscopy	
dNTP	 	 	 Deoxyribonucleotide	triphosphate	
DMEM		 	 Dulbecco’s	Modified	Eagle	Medium	
DMSO	 	 	 Dimethyl	Sulfoxide	
DNA	 	 	 Deoxyribonucleic	Acid	
DEPC	 	 	 Diethyl	Pyrocarbonate	
dsDNA	 	 Double	Stranded	DNA	
Edr	 	 	 Embryonal	Differentiation	Regulated	Gene	
EDTA	 	 	 Ethylenediaminetetraacetic	Acid	
eGFP	 	 	 Enhanced	Green	Fluorescent	Protein	Coding	Sequence	
eIF	 	 	 Eukaryotic	Translation	Initiation	Factor	
env	 	 	 Envelope	Gene	
ESCRT		 	 Endosomal	Sorting	Complex	Required	for	Transport	
E	site	 	 	 Exit	Site	
ESE	 	 	 Exonic	Splicing	Enhancer	
ESS	 	 	 Exonic	Splicing	Silencer	
FCS	 	 	 Fetal	Calf	Serum	
(US)FDA	 	 (United	States)	Food	and	Drug	Administration	
gag	 	 	 Group-specific	Antigen	Gene	
GDP	 	 	 Guanosine-5’-diphosphate	
GTP	 	 	 Guanosine-5’-triphosphate	
HIV-1	 	 	 Human	Immunodeficiency	Virus	I	
HEK293	 	 Human	Embryonic	Kidney	Cells	
HTLV	 	 	 Human	T-lymphotrophic	Virus	
IN	 	 	 Integrase	
ISE	 	 	 Intronic	Splicing	Enhancer	
ISS	 	 	 Intronic	Splicing	Silencers	
LTR	 	 	 Long	Terminal	Repeat	
MA	 	 	 Matrix	Protein	
miRNA	 	 Micro	RNA	
mRNA		 	 Messenger	RNA	
NC	 	 	 Nucleocapsid	Protein	
	
nef	 	 	 Negative	Regulatory	Factor	Gene	
NHR	 	 	 N-terminal	Heptad	Repeat	
NNRTI		 	 Non-nucleoside	Reverse	Transcriptase	Inhibitor	
NPC	 	 	 Nuclear	Pore	Complex	
NRTI	 	 	 Nucleoside	Reverse	Transcriptase	Inhibitor	
N-terminal	 	 Amino-terminal	
NtRTI	 	 	 Nucleotide	Reverse	Transcriptase	Inhibitor	
Nxf1	 	 	 Nuclear	Transcription	Factor,	X-Box	Binding	I	
ORF	 	 	 Open	Reading	Frame	
pbs	 	 	 Primer	Binding	Site	
PBS	 	 	 Phosphate	Buffered	Saline	
PCR	 	 	 Polymerase	Chain	Reaction	
Pi	 	 	 Phosphate	
PI	 	 	 Protease	Inhibitors	
PIC	 	 	 Pre-integration	Complex	
PEG10		 	 Paternally	Expressed	Gene	10	
pol		 	 	 Polymerase	Gene	
Poly(A)	 	 Polyadenylation	
ppt	 	 	 Purine-rich	Sequence	
PR	 	 	 Protease	
P	site	 	 	 Poly-peptide	Site	
P-TEFb	 	 Positive	Transcription	Elongation	Factor	b	
RF1	&	2	 	 Release	Factor	1	&	2	
RFU	 	 	 Relative	Fluorescence	Units	
RISC	 	 	 RNA-induced	Silencing	Complex	
RNA	 	 	 Ribonucleic	Acid	
RNAP	 	 	 RNA	Polymerase	II	
R	region	 	 Repeat	Region	
rRNA	 	 	 Ribosomal	RNA	
RSV	 	 	 Rous	sarcoma	virus	
RT	 	 	 Reverse	Transcriptase	
RTC	 	 	 Reverse	Transcription	Complex	
SEM	 	 	 Standard	Error	of	the	Mean	
siRNA	 	 	 Short	Interfering	RNA	
SMMRNA	 	 Small	Molecule	Modulator	of	RNA	
SOB	 	 	 Super	Optimal	Broth	
SP1	 	 	 Spacer	Peptide	1	
SP2	 	 	 Spacer	Peptide	2	
ssRNA		 	 Single	Strand	RNA	
SSE	 	 	 Secondary	Structural	Element	
TAR	 	 	 Transactivation	Response	
tat	 	 	 Trans-activator	of	Transcription	Protein	
TBE	 	 	 Tris/Borate/EDTA	Buffer	
tdT	 	 	 Tandem	Dimer	Tomato	Variant	
Tris	 	 	 Tris(hydroxylmethyl)aminomethane	
tRNA	 	 	 Transfer	RNA	
T	site	 	 	 Entry	Site	
Tsg101	 	 Tumour	Susceptibility	Gene	101	
vif	 	 	 Viral	Infectivity	Factor	Gene	
	
vpr	 	 	 Viral	Protein	R	Gene	
Vps	 	 	 Vacuolar	Protein	Sorting	
Vpu	 	 	 Viral	Protein	Unique	





During	 the	 study	 shorthand	 for	 each	 of	 the	 sub-elemental	 constructs	 was	
developed.	 Each	 of	 the	 constructs	 was	 given	 a	 three-letter	 code	 to	 determine	
what	they	encoded.	The	first	letter	encodes	for	the	slippery	sequence,	the	second	
is	the	intercodon	and	the	third	is	the	secondary	structural	element;	for	example,	






Human	 immunodeficiency	 virus	 I	 (HIV-1)	 is	 a	 pathogenic	 retrovirus	 that	
specifically	 targets	 specific	 human	 immune	 cells	 and	 their	 ability	 to	 replicate.	
With	the	virus’	mode	of	infection,	the	first	cells	employed	by	the	host	to	defend	
against	the	virus	are	the	cells	whose	replication	is	impaired.	HIV-1	is	the	primary	
cause	of	 acquired	 immune	deficiency	 syndrome	 (AIDS).	 Since	 its	 first	 reported	
diagnosis	in	1981	(Masur	et	al.	1981),	AIDS	has	infected	over	75	million	people	
and	 caused	 an	 estimated	36	million	 deaths	worldwide	 (United	Nations,	 2013).	
Although	HIV-1	leads	to	death	indirectly	through	rare	infections	in	many	cases,	
simply	 having	 the	 virus	 present	 does	 not	 immediately	 cause	 host	mortality.	 If	
HIV-1	is	stopped	early	in	its	life	cycle	progression	into	AIDS	will	be	halted,	as	it	
often	 requires	 a	 high	 viral	 titre	 to	 cause	 adverse	 effects	 to	 the	 host.	 Current	
antiretroviral	therapy	is	not	effective	in	all	patients,	expensive	and	inaccessible	
to	 the	 people	 in	 developing	 nations,	 like	 those	 in	 Sub-Saharan	 Africa,	 which	
accounted	 for	 67%	 of	 AIDS-associated	 deaths	 in	 2010	 (World	 Health	 Org.	 &	
UNICEF,	2011).	Due	to	the	lack	of	efficacy	in	the	current	treatments,	there	is	poor	
distribution	 of	 treatment	 in	 areas	 with	 low	 socio-economic	 standing.	 With	 an	
increase	 in	 treatment	efficacy	 (a	potential	 cure),	 there	would	be	an	 increase	 in	
the	funding	and	distribution	of	treatment	for	those	in	need.	
My	study	focuses	on	a	highly	conserved	-1	programmed	ribosomal	frameshifting	
(-1PRF)	 mechanism	 in	 the	 viral	 RNA	 translation	 pathway.	 This	 pathway	 is	
relatively	unique	 to	 retroviridae,	 however	 importantly,	 now	a	 small	 number	of	
human	genes	have	been	shown	to	carry	out	-1PRF	and	therefore	this	discovery	
has	 the	potential	 to	halt	 any	 further	development	of	 this	mechanism	as	a	drug	
target.	The	focus	of	the	study	is	to	further	understand	the	characteristics	of	each	
of	 HIV-1	 and	 human	 orthologue,	 paternally	 expressed	 gene	 10	 (PEG10)	 sub-
elements	 and	 how	 compounds	 designed	 to	 disturb	 this	 pathway	 in	 HIV-1	 for	













reverse	 transcriptase,	 integrase	 and	 various	 accessory	 proteins	 used	 for	 the	 avoidance	 of	 host	
immune	response.	This	is	surrounded	by	the	matrix	and	protease.	Finally	there	is	the	outer	lipid	
membrane,	 which	 is	 studded	 with	 gp120	 docking	 glycoproteins	 attached	 via	 a	 gp41	
transmembrane	glycoprotein.	In	most	cases	the	gp120	glycoprotein	binds	to	the	CD4	receptor	on	










place,	via	 the	cleavage	of	 the	gag-pol	polyprotein	 into	 the	capsid	and	nucleocapsid	proteins.	At	
























membrane,	 namely	 T-lymphocytes	 and	 macrophages	 (Chan	 et	 al.	 1998).	
Therefore	 the	 targets	 within	 the	 human	 host	 are	 the	 very	 cells	 designed	 to	
defend	against	such	potentially	pathogenic	microorganisms.	For	this	reason	it	is	
unlikely	 that	 the	 host’s	 immune	 system	 could	 be	 fine-tuned	 to	 eradicate	 the	
virus,	meaning	that	to	defeat	the	virus,	specific	pathways	must	be	targeted.		
Due	 to	 the	 complexity	 of	 replication	 of	 retroviridae,	 the	 life	 cycle	 of	HIV-1	 has	




The	human	host	 is	exposed	 to	 the	HIV-1	virus	 through	the	absorption	of	 fluids	




by	 the	 host	 immune	 system.	 The	 CD4+	 T-lymphocytes	 are	 the	 host’s	 usual	
mechanism	 for	 the	 destruction	 of	 any	 foreign	 body	 or	 potential	 pathogen	 that	
enters	the	host	system.	However	in	the	case	of	HIV-1	infection	this	leads	to	the	
host’s	demise	(Perelson	et	al.	1993).			
There	 are	 two	 proteins	 located	 on	 the	 virion	 essential	 for	 fusion	 of	 the	 HIV-1	
virion	to	the	CD4+	cell.	These	proteins	are	the	transmembrane	protein	gp41	and	
the	surface	protein	gp120.	Firstly,	gp120	directly	binds	 to	 the	CD4	receptor	on	








pre-hairpin	 intermediate	 state.	 Following	 this,	 the	 C-terminal	 heptad	 repeats	




pore	 in	 this	 state	 is	 neither	 fully	 open	 or	 closed,	 therefore	 is	 in	 a	 state	 of	 flux	
where	it	 is	capable	of	reverting	back	to	closed	or	forming	a	robust	pore	via	the	
CHRs	 binding	 to	 the	 trimeric	 coiled	 coil	 of	 the	 NHRs	 (Tan	 et	 al.	 1997).	 The	
binding	of	these	proteins,	via	three	hydrophobic	residues	located	in	the	pocket-






A.	 The	 gp120	 glycoprotein	 (white)	 on	 the	 viral	 membrane	 binds	 to	 the	 CD4	 receptor	 (cyan),	
located	on	the	host	cell	membrane.	gp41	is	shown	in	blue.	The	two	pink	lines	to	which	the	CD4	is	
bound	 are	 the	 host	 cell	membrane.	 The	 pink	 lines	 to	which	 the	 gp41	 are	 bound	 are	 the	 viral	
membrane.	 B.	 This	 binding	 causes	 exposure	 of	 the	 co-receptor	 binding	 regions	 of	 the	 gp120	
glycoproteins,	shown	in	green.	C.	Binding	of	the	CD4	also	causes	a	conformational	change	in	the	
gp41	 glycoprotein	 allowing	 exposure	 of	 its	 N-terminal	 heptad	 repeats	 (NHRs	 in	 red)	 and	




two	membranes	 together,	when	this	occurs	 in	more	 than	one	binding	event	 in	close	proximity,	
the	two	membranes	split	forming	a	labile	pore.	F.	The	NHRs	and	CHRs	bind	together	to	for	a	six-





















Once	 in	 the	 host	 cell	 there	 are	 contrary	 views	 as	 to	 when	 the	 capsid	
disassociates,	with	speculation	around	whether	the	event	takes	place	prior	to	or	
after	reverse	transcription	of	the	RNA	genome.	It	is	certain	that	the	event	takes	
place	before	entry	of	 the	cDNA	 into	 the	nucleus	as	 the	nuclear	pore	complexes	
(NPCs)	have	an	inner	diameter	of	only	39nm,	smaller	than	an	intact	capsid	of	50-
60nm	in	diameter	(Campbell	&	Hope,	2015).	The	process	of	uncoating	occurs	in	
two	 steps;	 the	 first	 is	 the	 loss	 of	 integrity	 that	 must	 occur	 in	 the	 host	 cell	




There	 are	 three	 possible	 mechanisms	 by	 which	 the	 pre-integration	 complex	
(PIC)	can	exit	the	capsid.	The	leading	theory	for	several	years	was	that	the	capsid	








definitive	evidence	 favours	either	of	 the	 last	 two	theories,	however	 it	has	been	
proven	 that	 the	capsid	proteins	are	 still	 associated	with	 the	PIC	 in	 the	nucleus	
(Zhou	et	al.	2011).	
Whilst	 this	 capsid	 mechanism	 is	 occurring	 and	 the	 viral	 constituents	 are	
traveling	 towards	 the	 nuclear	 envelope,	 the	 viral	 reverse	 transcriptase	 (RT)	
binds	 to	 the	 viral	 positive	 sense	 ssRNA.	Once	 bound	180nt	 upstream	 to	 the	 5’	
end	of	the	ssRNA	a	host	Lys3	tRNA	binds	to	the	upstream	primer	binding	site	to	
act	 as	 the	 RNA	 primer	 (pbs	 [Hu	 &	 Hughes,	 2012]).	 As	 the	 RT	 transcribes	 the	
repeat	 (R)	 region	 of	 the	 RNA	 into	 DNA	 an	 RNA:DNA	 duplex	 forms.	 RNase	 H	
breaks	down	the	RNA	component	of	the	duplex.	This	region	is	complementary	to	
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the	sequence	at	 the	3’	end	of	 the	RNA.	Once	the	RT	has	reached	the	end	of	 the	
RNA	and	the	template	RNA	has	been	removed	from	the	duplex,	the	synthesised	
DNA	strand	 (-)	 can	be	used	as	a	primer	 for	 the	 transcription	of	 the	 rest	of	 the	
RNA.	As	the	virion	contains	two	copies	of	the	same	RNA	it	 is	 important	to	note	







line).	 B.	 The	 viral	 reverse	 transcriptase	 has	 begun	 transcription	 of	 the	 U5	 region,	 creating	 a	
length	 of	 minus	 strand	 DNA	 (red,	 arrow	 shows	 direction	 of	 transcription).	 Whilst	 this	 is	
occurring,	RNase	H	is	degrading	the	RNA	template	(dashed	line).	C.	Due	to	a	repeat	region	(R)	at	
each	end	of	the	viral	genome,	once	the	transcription	of	the	region	has	taken	place	at	the	5’	end,	
the	 new	 DNA	 fragment	 relocates	 to	 the	 3’	 R	 region	 and	 acts	 as	 a	 primer	 for	 transcription.	 D.	
Transcription	of	 the	 rest	of	 the	RNA	 template	occurs.	During	 this	process	 the	RNase	H	activity	
degrades	the	temple	strand,	apart	from	the	purine-rich	sequence	(ppt,	blue).	The	ppt	region	acts	
as	the	primer	for	the	plus	strand	DNA.	E.	Plus	strand	synthesis	occurs	and	the	first	18	nucleotides	
are	 reverse	 transcribed.	 This	 removes	 the	 tRNA	 on	 the	 minus	 strand	 through	 RNase	 action,	






























































two	 strands	 have	 formed	 double	 stranded	 DNA	 (dsDNA),	 it	 forms	 the	 pre-







host	DNA	 (black)	 is	 broken	 five	nucleotides	 up	 from	 the	 IN	 and	 the	3’	 end	of	 the	 viral	DNA	 is	
attached	to	the	host	DNA.	D.	Shows	an	intermediate	step	that	contains	five	unpaired	nucleotides.	
E.	Host	DNA	repair	machinery	repairs	the	five	nucleotides	and	cleave	the	5’	ends	of	the	viral	DNA.	









the	 3’	 end	 of	 the	 viral	 DNA	 strands	 carried	 out	 by	 a	 nucleophilic	 group	
(Engelman	et	al.	 1991).	The	preferred	 region	 for	 integration	 is	 thought	 to	be	a	
palindromic	sequence	(Carteau	et	al.	1998).	However	the	exact	target	for	the	IN	
is	 still	 unknown,	 although	 some	 groups	 have	 shown	 HIV	 has	 a	 preference	 for	
regions	 of	 the	 genome	 that	 are	 transcriptionally	 active	 (Schröder	 et	al.	 2002).	
This	terminal	cleavage	reaction	exposes	a	3’-OH	group	and	causes	a	dinucleotide	
5’	overhang.	Whilst	the	reaction	is	taking	place	IN	breaks	the	host	DNA	and	via	a	
single	 step	 transesterification	 reaction	 joins	 the	viral	 3’	 end.	This	 intermediate	
A B C D E F
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state	 leaves	 a	 five	 nucleotide	 unpairing	 in	 the	 host	 DNA	 and	 a	 two	 nucleotide	
overlap	on	the	5’	end	of	the	viral	DNA	(Ciuffi	&	Bushman,	2006).	Host	DNA	repair	
machinery	 removes	 the	 viral	 DNA	 overlap	 and	 is	 thought	 to	 insert	 new	
nucleotides	to	pair	the	five	unpaired	host	DNA.	This	five	base	pair	region	occurs	
at	 both	 ends	 of	 the	 insert	 and	 therefore	 creates	 a	 duplication	 of	 sequence	
(Craigie	&	Bushman,	2012).		
Although	 long	 terminal	 repeats	 (LTRs)	 are	 contained	 at	 either	 end	of	 the	 viral	
genome,	the	transcription	efficiency	of	these	is	low	and	the	transcripts	produced	
are	 only	 in	 a	 short	 form	 known	 as	 a	 transactivation	 response	 (TAR)	 RNA	
stemloop.	 To	 produce	 long	 transcripts	 at	 a	 higher	 efficiency,	 HIV-1	 uses	 the	
trans-activator	 of	 transcription	 (tat)	 protein	 and	 the	 positive	 transcription	
elongation	factor	b	(P-TEFb),	which	is	made	up	of	cyclin	T1	and	cyclin	dependent	
kinase	9	(Cdk9)	to	form	a	complex	that	binds	to	the	TAR	stemloop	(Debaisieux	et	
al.	 2012).	 The	 binding	 of	 these	 proteins	 causes	 phosphorylation	 of	 the	 RNA	
polymerase	 II	 (RNAP),	 this	allows	the	RNAP	to	 transcribe	 the	remainder	of	 the	
DNA	and	complete	 the	pre-mRNA	 transcription	process	efficiently	 (Zheng	et	al	
2005).	
As	well	as	increasing	the	transcription	efficiency	of	the	HIV-1	infected	cell	the	tat	
protein	 can	 be	 secreted	 from	 that	 cell	 and	 enter	 other	 host	 cells	 (Rayne	 et	al.	
2010).	In	doing	so	it	can	affect	the	function	of	many	immune	cells	and	is	known	
to	 change	 the	 expression	 of	 immunoregulatory	 cytokines	 (Rayne	 et	 al.	 2004),	




The	 HIV-1	 genome	 encodes	 nine	 genes:	 gag,	 pol,	 env,	 tat,	 nef,	 vif,	 vpr	 and	 vpu.	
Some	 of	 the	 copies	 of	 mRNA	 produced	 from	 the	 genome	 are	 for	 new	 viral	
particles	while	others	act	as	true	mRNAs	to	synthesise	the	proteins	that	form	the	
capsid	 and	 associated	 viral	 proteins.	However	unlike	 like	 larger	 organisms	 the	
key	 to	 retroviral	 success	 is	 being	 a	 small	 unit,	 able	 to	move	 freely	 around	 the	
host	 with	 less	 likelihood	 of	 detection.	 In	 multicellular	 organisms	 cell	 size	 has	
been	 linked	 to	 the	 size	 of	 the	 nucleus,	 which	 in	 turn	 is	 linked	 the	 size	 of	 its	
nucleic	acid	content.	For	 this	reason	the	genome	of	HIV-1	 is	heavily	condensed	
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allowing	 the	virus	 to	be	 smaller	 as	 a	whole	 (Ilie	et	al.	 2006).	To	accommodate	
this	condensed	genome	many	of	the	encoded	genes	are	overlapping.	This	method	
allows	 for	maximum	 gene	 expression	with	minimal	 genome	 size	 but	 creates	 a	
new	 issue,	 how	 to	 separate	 the	 mRNA	 transcript	 into	 its	 individual	 gene	
components.	To	separate	these	encoded	genes	HIV-1	has	four	different	5’	splice	
sites	 and	 eight	 3’	 sites,	 which	 can	 be	 alternatively	 spliced	 by	 cis-regulatory	
elements	to	create	approximately	thirty	RNAs,	including	the	approximately	9kb	
transcript	 that	 encodes	 the	gag-pol	 region	 (Chen	&	Manley,	 2009;	 Tange	 et	al.	
2001).	 Splicing	 of	 the	 pre-mRNA	 is	 controlled	 by	 binding	 of	 the	 mRNA	 to	 a	
complex	of	cellular	factors	and	is	tightly	regulated	by	exonic	and	intronic	splicing	
enhancers	(ESEs	and	ISEs)	as	well	as	exonic	and	intronic	splicing	silencers	(ESSs	
and	 ISSs).	 These	 factors	 are	 linked	 to	 splicing	 site	 recognition	 and	 the	 up-
regulation	or	down-regulation	of	splicing	(Karn	&	Stolzfus,	2012).	These	spliced	
mRNAs	 are	 then	 exported	 from	 the	 nucleus	 via	 nuclear	 pores.	 However	 as	
indicated	above	not	all	pre-mRNA	transcripts	are	spliced	to	become	messengers	
for	 viral	 proteins.	 The	 export	 of	 the	 full	 length	 transcripts	 used	 as	 new	 viral	
genomes	 into	 the	 cytoplasm	 is	 mediated	 by	 the	 Rev	 protein	 (Pollard	 Malim,	
1998).	 The	 Rev	 protein	 binds	 to	 a	 351nt	 stem-loop	 structure	 in	 the	 env	 gene	
allowing	the	transcript	to	avoid	degradation	by	host	nuclear	proteins.	Rev	then	
interacts	with	 host	 Crm1	 to	 export	 the	 full	 length	 transcripts	 through	 nuclear	
pores	 and,	 with	 hydrolysis	 of	 GTP,	 the	 complex	 is	 destabilised	 and	 full	
transcripts	released	into	the	host	cell	cytoplasm	(Perales	et	al.	2005).	



















mannosidase	 activity	 and	 subsequently	 the	 addition	 of	 other	 carbohydrate	
components	to	produce	complex	glycans	(Pritchard	et	al.	2015).	This	process	of	
gp120	 glycosylation	 can	 vastly	 affect	 the	 way	 the	 virion	 is	 detected	 by	 host	
polyclonal	antibodies.	Differing	levels	of	mannose	and	N-glycans	on	the	proteins	
can	change	the	ability	of	the	virus	to	go	undetected	even	with	small	changes	in	
glycosylation	 (Raska	 et	 al.	 2010).	 Once	 the	 mature	 gp120	 and	 gp41	 are	
processed	in	the	Golgi	apparatus,	they	are	transported	via	non-lysosomal	acidic	
compartments	to	the	cell	membrane	to	become	the	transmembrane	proteins	for	
the	 new	 virions	 (Willey	 et	 al.	 1988).	 For	 efficient	 creation	 of	 new	 virions	 the	
concentration	of	gp160	must	be	high	within	the	Golgi	to	ensure	gp160	binds	CD4	
in	the	Golgi.	Unfortunately	the	half-life	of	this	interaction	is	4.5	hours,	otherwise	
gp160	 is	 degraded.	 Kimura	 et	 al.	 (1994)	 discovered	 that	 Vpu	 destabilises	 the	
interaction	between	 gp160	 and	CD4,	 allowing	 it	 to	 pass	 through	 the	Golgi	 and	
form	mature	glycoprotein	in	high	concentration.	
The	55-kDa	Gag	polyprotein	precursor	is	synthesised	in	the	cytoplasm	and	soon	
after	 becomes	myristoylated	 via	 the	 addition	 of	 a	 myristoyl	 lipid	 group	 to	 an	
amino-terminal	 glycine	 within	 its	 matrix	 domain	 (Provitera	 et	 al.	 2006).	 This	
modification	 causes	 the	Gag	polyprotein	 to	 become	 lipophilic	 and	 the	 complex	
localises	 to	 the	 plasma	 membrane	 to	 form	 the	 capsid	 of	 the	 immature	 virion	
(Lingappa	&	Thielen,	2009).	The	Pol	protein	 is	produced	as	part	of	 the	Gag-Pol	
polyprotein	 through	 a	 key	 focus	 of	 this	 thesis,	 the	 translational	 frameshifting	
event,	discussed	 in	detail	 later.	Due	 to	 the	presence	of	 the	Gag	amino-terminal	
glycine	in	the	160-kDa	Gag-Pol	polyprotein	it	acts	in	a	similar	manner	to	Gag	and	
therefore	 accumulates	 on	 the	 cell	 membrane	 alongside	 Gag	 (Haraguchi	 et	 al.	
2010).	
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between	 the	 gp41	 cytoplasmic	 tail	 and	 the	 amino-terminus	 of	 Gag	 has	 been	







members	 of	 the	 class	 E	 vacuolar	 protein	 sorting	 (Vps)	 subunits	 used	 by	
Saccharomyces	to	bud.	These	proteins	are	also	present	in	humans	and	therefore	
can	 be	 sequestered	 by	 HIV-1	 for	 budding	 of	 the	 cell	 membrane;	 through	
interaction	 of	 binding	 domains	 ESCRT-II	 and	 III	 are	 bound	 to	 the	 complex.	 As	
this	occurs	 in	 each	of	 the	Gag	proteins	present	on	 the	 cell	membrane,	 charged	
multivesicular	 body	 proteins	 (CHMPs)	 present	 in	 ESCRT-III	 form	 lattices	
between	 the	proteins	 (Zheng	et	al.	 2005).	After	accumulation	and	 formation	of	
lattices,	 ATPase	 Vps4	 is	 recruited	 for	 the	 hydrolysis	 of	 ATP,	 which	 causes	 the	
immature	virion	to	bud	off	the	cell	membrane	(Jouvenet	et	al.	2011).		
The	Gag	polyprotein	contains	five	proteolytic	sites	that	act	as	targets	for	the	viral	
protease	 (PR)	 enzyme.	 After	 the	 immature	 virion	 buds	 off	 the	 host	 cell	
membrane,	 PR	 is	 activated	 and	 forms	 a	 proteolytic	 homodimer	 (Pettit	 et	 al.	
2003).	 PR	 then	 cleaves	 Gag	 at	 each	 of	 these	 sites	 forming	 three	 proteins	 and	
three	 peptides	 (Freed,	 2015).	 Each	 of	 these	 proteins	 and	 peptides	 has	 varying	
functions	within	the	structure	and	replication	cycle	of	HIV-1	(Freed,	2013).			
The	first	 to	be	cleaved	from	the	amino-terminus	 is	 the	Matrix	(MA)	protein.	 Its	
major	 role	 is	 to	 target	 and	 bind	 to	 the	 plasma	membrane	 and	 recruit	 the	 Env	
protein	(Lee	et	al.	1997).	An	interesting	second	function	of	the	MA	protein	is	the	
apparent	 nuclear	 localisation	 of	 viral	 particles	 within	 a	 non-dividing	 host	 cell	
(Burkrinsky	et	al.	 1993).	This	 is	 especially	 important	when	 the	already	 limited	
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number	of	host	cells	able	 to	be	 infected	by	 the	virus	 is	 taken	 into	account,	 if	 it	
was	limited	to	only	dividing	cells,	the	number	would	be	further	decreased,	which	
would	be	highly	inefficient.	
The	 next	 protein	 cleaved	 from	 the	 Gag	 polyprotein	 is	 the	 Capsid	 (CA)	 protein	
that	acts	as	the	major	structural	element	for	the	mature	virion.	Once	cleaved	and	
folded,	 the	 CA	 forms	 the	 conical	 capsid	 core	 that	 surrounds	 the	 viral	 genome.	
There	 are	 several	 known	 functions	 of	 the	 capsid	 apart	 from	 the	 obvious	
protection	 of	 the	 genetic	material	 from	 host	 nucleases;	 CA	 interacts	with	 host	
cellular	 proteins	 to	 ensure	 localisation	 into	 the	 host	 nucleus	 for	 integration	 of	
viral	DNA	into	the	host	genome	(Campbell	&	Hope,	2015).		Once	the	protein	has	




within	 the	 viral	 RNA	 genome	 (Sundquist	&	Kräusslich,	 2012).	 	 This	 allows	 the	
virus	 to	 locate	 its	 own	 RNA/DNA	 and	 ensure	 correct	 packaging	 of	 its	 viral	
components.	As	with	most	of	 the	genetic	 elements	of	HIV-1	 it	 has	 a	 secondary	
function,	 it	 remodels	 the	 RNA	 to	 create	 a	 thermodynamically	 stable	 structure	
that	is	much	easier	for	the	reverse	transcriptase	to	bind	to	and	act	upon	(Levin	et	
al.	 2010).	 It	 does	 this	 by	destabilising	 the	nucleic	 bonds	 via	 binding	 of	 its	 two	
zinc	 finger	 domains	 to	 guanine-thymine	 (or	 uracil)	 rich	 regions	 of	 viral	 RNA,	
causing	 the	 secondary	 structures	 to	 disassociate	 and	 facilitates	 formation	 of	
linear	RNA.	
Although	the	SP1	peptide	region	is	only	14	residues	long,	it	is	highly	conversed	




the	 peptide	 folds	 may	 be	 the	 key	 to	 triggering	 virus	 assembly	 and	 it	 can	 be	
affected	by	 cellular	 conditions	 (Datta	et	al.	 2011).	 This	 could	 indicate	 that	 SP1	
acts	 as	 an	 environmental	 trigger.	 If	 the	 conditions	 are	 suboptimal	 for	 viral	
budding	it	halts	the	process	until	they	improve.	
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The	 SP2	 peptide	 is	 not	 as	 well	 studied	 as	 SP1,	 and	 as	 yet	 a	 function	 for	 the	
peptide	has	not	been	discovered.	de	Marco	et	al.	 (2012),	 showed	 that	although	
the	 SP2	peptide	may	not	 have	 a	 function	 as	 a	 cleaved	peptide,	 by	mutating	 its	
cleavage	 sites	 the	 viral	 infectivity	 was	 abolished,	 indicating	 that	 the	 element	
most	likely	acts	as	a	spacer	between	NC	and	p6.	
The	p6	peptide	is	arguably	the	most	important	of	the	three	peptides	encoded	in	
the	Gag	 polyprotein.	 As	 previously	 discussed,	 the	 p6	 peptide	 acts	 as	 a	 binding	
position	for	the	Tsg101	region	of	ESCRT-1	and	therefore	acts	as	a	key	component	





Subsequent	 to	 the	Gag	polyprotein	cleavage,	 the	Gag-Pol	polyprotein	 is	cleaved	
into	 the	 Gag	 and	 Pol	 polyproteins	 before	 being	 further	 reduced	 into	 their	
constitutive	proteins.	In	the	case	of	Gag-Pol	there	are	an	extra	four	cleavage	sites	
to	 produce	 four	 functional	 proteins,	when	 compared	 to	 the	 Gag	 protein	 alone.	
These	 proteins	 are	 protease	 (PR),	 p51	 (RT),	 p15	 (RT)	 and	 integrase	 (IN).	
However	due	to	the	frameshift	mechanism	located	at	the	end	of	the	NC	region	of	











transcription	 the	 RNA	 template	 must	 be	 degraded,	 this	 is	 where	 the	 protein	





The	 final	 protein	 encoded	 in	 the	 Gag-Pol	 polyprotein	 is	 integrase	 (IN).	 As	
previously	 discussed,	 IN	 is	 used	 to	 integrate	 the	 viral	 DNA	 into	 the	 host	 DNA	








the	 viral	 RNA	 genome	 (Levy	 et	 al,	 2004).	 These	 events	 occur	 incredibly	
frequently	across	the	HIV-1	genome	and	have	been	shown	to	take	place	two	to	
twenty	 times	 per	 replication	 cycle	 (Charpentier	 et	 al.	 2006).	 This	 remarkably	
high	 recombination	 rate	 allows	 the	 virus	 to	 randomly	 assort	 fragments	 of	 its	
genome	and	therefore	rapidly	change	the	way	certain	pathways	act.	This	is	of	a	
large	significance	as	many	drug	compounds	are	targeted	at	simple	pathways	in	
the	 replication	 cycle,	 such	 as	 reverse	 transcription.	 Drugs	 such	 as	
Azidothymidine	(AZT)	were	found	to	affect	the	viral	load	of	HIV	positive	patients,	
however	 this	 effect	 can	 be	 short	 lived	 as	 the	 virus	 mutates	 and	 acquires	 the	
ability	to	remove	AZT	by	recruitment	of	ATP	(Tu	et	al.	2010).			
The	other	mechanism,	which	causes	mass	mutations	in	HIV-1,	is	a	high	error	rate	
in	 the	 reverse	 transcription	 process	 itself.	 The	 rate	 at	 which	 an	 incorrect	
nucleotide	 is	 inserted	 into	 the	HIV-1	DNA	genome	 is	 a	 remarkable	 1	mutation	
per	70	polymerised	nucleotides	(Roberts	et	al.	1988).	This	mechanism	unlike	the	
recombination	 mutational	 pathway	 creates	 point	 mutations,	 which	 are	 more	
likely	 to	 result	 in	 a	 fully	 functional	 virus	 than	 the	 large	 mutations	 seen	 in	
recombination.	However	due	to	the	scale	of	mutation	of	that	recombination	and	
the	alarming	rate	at	which	it	occurs	in	HIV-1,	recombination	gives	a	much	higher	







for	 the	 eradication	 of	 HIV-1	 infection,	without	 the	 need	 for	 host	machinery	 to	
intervene.	However	as	there	are	similarities	to	host	protein	structure	or	activity,	
several	 drugs	 form	 a	 potential	 toxic	 risk	 to	 the	 host.	 For	 example	 it	 has	 been	
shown	that	extensive,	long-term	treatment	with	nucleotide	reverse	transcriptase	
inhibitors	 (NRTIs)	 inhibits	 mitochondrial	 polymerase	 ϒ	 (Kakuda,	 2000).	 This	
inhibition	leads	to	mitochondrial	dysfunction,	which	in	turn	can	be	causative	to	
several	 life-threatening	 conditions	 such	 as	 nephrotoxicity	 and	 kidney	 failure.	
Knowledge	 of	 both	 the	 viral	 and	 human	 cellular	 cycles	 is	 important	 for	 the	











with	a	7-methylguanylate.	Next	 the	3’	 terminal	end	 is	cleaved	at	 the	end	of	 the	
transcript	 and	~	 150	 adenylates	 added	 to	 form	 a	 3’	 poly(A)	 tail	 (Lodish	 et	al.	
2000).	 	 An	 enzyme-protein	 complex	 known	 as	 the	 spliceosome	 carries	 out	
removal	of	the	intronic	regions	of	the	primary	transcript,	the	pre-mRNA.	Each	of	








the	 sugar	 of	 an	 adenine	 in	 a	 chemical	 process	 known	 as	 transesterfication.	
During	 the	subsequent	step	2	reaction	the	guanine	nucleotide	bond	 is	attacked	







involved	 in	 the	 release	 from	 the	 nucleus	 into	 the	 cell	 cytoplasm	 (Carmody	 &	
Wente,	2009).	
The	 translation	 process	 is	 made	 up	 of	 three	 distinct	 fundamental	 steps:	
initiation,	elongation	and	release.	Before	translation	can	initiate,	initiation	factor	
proteins	 (eIF1,	 eIF1A,	 eIF2-GTP-Met-tRNAMet,	 and	 eIF3)	 bind	 to	 the	 small	
subunit,	forming	the	43S	pre-initiation	complex	(Jackson	et	al.	2010).	Whilst	the	
43S	 complex	 is	 forming,	 the	 mRNA	 is	 being	 activated	 for	 translation	 by	
unwinding	of	 the	cap-proximal	region	upstream	of	 the	 initiation	codon	AUG	by	
two	subunits	of	the	eIF4G	complex,	eIF4F	and	eIF4B.	The	43S	ribosome	complex	
becomes	bound	 to	 the	7methyl	G	 cap	at	 the	end	of	 the	unwound	 region	of	 the	
mRNA,	facilitated	by	the	third	eIF4G	subunit,	eIF4E,	and	begins	scanning	through	
the	mRNA	in	a	5’	to	3’	direction	until	it	comes	in	contact	with	the	AUG	start	site	
within	 a	 preferred	 Kozak	 sequence	 (A/GCCXCCAUGG)	 region,	which	 forms	 the	
48S	initiation	complex.	This	recognition	of	the	start	site	causes	a	conformational	
change	 in	 the	 complex,	 creating	a	 closed	conformation.	 In	 this	 ribosomal	 state,	
eIF1	is	displaced	allowing	hydrolysis	of	eIF2-bound	GTP	and	Pi	release,	via	eIF5	
mediated	action	(Pisareva	&	Pisarev,	2014).	Arrival	of	the	60S	ribosomal	subunit	
causes	 disassociation	 of	 eIF2-GDP,	 eIF1,	 eIF3,	 eIF4B,	 eIF4F	 and	 eIF5,	 again	












Initiation:	 (a)	 The	 40S	 ribosomal	 subunit	 is	 bound	 by	 initiation	 factors,	 forming	 the	 43S	 pre-
initiation	complex.	During	this	process	eIF-4E	and	eIF-4B	are	activating	the	mRNA	by	unwinding	
the	 cap-proximal	 region,	 whilst	 eIF-2	 recruits	 the	 initiator	 tRNAmet.	 (b)	 The	 43S	 subunit	 then	






the	 first	peptide	bond	 (d)	Causing	 translocation	of	 the	 complex	on	 the	 ribosome,	 accompanied	
with	a	 relative	move	of	 three	nucleotides	 from	the	mRNA.	eEF-2	mediated	 translocation	of	 the	
tRNAs	 facilitates	 the	move	 of	 	 the	 two	 tRNAs	 into	 the	E	 and	P	 sites	 allowing	 another	 the	 next	
aminoacyl-tRNA	tRNA	to	enter	 the	A	site.	This	process	continues	 iteratively	until	 the	ribosome	
meets	a	termination	codon.	
Termination:	 (a)	 The	 stop	 codon	 recruits	 a	 release	 factor	 instead	 of	 a	 tRNA.	 (b)	 The	 release	











The	next	stage	of	 translation	 is	 the	elongation	phase,	where	 the	ribosome	uses	
the	 mRNA	 as	 a	 triplet	 codex	 to	 create	 the	 appropriate	 peptide	 chain.	 The	
aminoacylated	tRNA	arrives	at	the	ribosome	as	part	of	a	ternary	complex,	bound	
to	 the	 elongation	 factor	 eEF-1α.	 The	 transfer	 RNAs	 (tRNAs)	 are	 70-80	
nucleotides	in	length	and	have	a	conserved	cloverleaf	secondary	structure,	with	
a	three	dimensional	‘boomerang’	structure	with	the	anticodon	at	the	outer	edge	







is	 fidelity	checked	against	 the	A	site	codon	of	 the	mRNA	sequence.	 If	 there	 is	a	
cognate	 match,	 the	 GTP	 bound	 to	 the	 tRNA	 ternary	 complex	 is	 hydrolysed	 to	




the	 catalytic	 site	 until	 the	 hydrolysis	 of	 GTP.	 This	 rate-limiting	 step	 slows	 the	
reaction	 allowing	 time	 for	 tRNAs	 with	 non	 cognate	 anticodons	 to	 dissociate	
before	accommodation	and	peptide	transfer	can	occur.	As	the	elongation	factor	
exits	 the	 ribosome,	 the	 amino	 acid	 bound	 to	 the	 tRNA	 in	 the	 A	 site	 is	 now	
juxtaposed	at	the	catalytic	site	with	the	P	site	peptidyl-tRNA	(initially	simply	Met	
–tRNA)	and	that	can	form	a	peptide	bond	with	the	incoming	amino	acid	in	the	A	
site.	The	peptide	bond	 formed	between	 these	 two	amino	acids	occurs	with	 the	
transfer	of	 the	P	site	peptide	(or	Met)	to	the	A	site	amino	acid.	This	reaction	 is	
facilitated	 by	 rRNA	 at	 the	 peptidyl	 transferase	 centre	 of	 the	 large	 subunit,	 but	
catalysis	 is	 initiated	by	a	 ribose	hydroxyl	of	 the	 terminal	nucleotide	A	of	 the	P	





translocation	 the	mRNA	 shifts	 three	 nucleotides	 downstream	 placing	 the	 next	
codon	 into	 the	 A	 site.	 As	 the	 peptidyl	 tRNA	 enters	 the	 P	 site	 the	 occupying	
uncharged	 tRNA	 is	pushed	 into	 the	E	 site	 for	 eventual	 exit	 from	 the	 ribosome.	
This	 leaves	 the	 A	 site	 open	 and	 ready	 for	 another	 aminoacyl	 tRNA	 to	 bind,	
causing	 the	 uncharged	 tRNA	 to	 vacate	 the	 E	 site.	 As	 with	 most	 reactions,	 the	
elongation	 factors	 are	 reused	 via	 a	 GDP-GTP	 transfer	 catalysed	 by	 eEF-1βϒ,	
which	recharges	the	eEF-1α.	
The	 final	 step	 of	 translation	 is	 termination.	 This	 process	 occurs	 when	 the	
ribosome	reaches	a	UAAN,	UAGN	or	UGAN	four	base	stop	signal	(McCaughan	et	
al.	 1995	 PNAS,	 and	 Brown	 et	 al.	 2015)	 with	 upstream	 and	 downstream	
surrounding	nucleotides	influencing	the	efficiency	of	the	signal.	The	recognition	
of	 the	 stop	 site	 by	 the	 ribosome	 causes	 the	 recruitment	 of	 eRF1	 (eukaryotic	
release	 factor	 1)	 which	 binds	 directly	 to	 the	 four	 base	 stop	 signal	 causing	
hydrolysis	 of	 the	 bond	 between	 the	 P	 site	 tRNA	 and	 the	 polypeptide	 chain	
(Brown	and	Tate,	1994;	Brown	et	al.	2015).		This	releases	the	polypeptide	chain	
from	 the	 ribosome,	 then	 the	 ribosomal	 subunits	 and	 mRNA	 disassociate	 and	
await	further	use	in	the	cytoplasm.	
An	 important	 note	 on	 translation	 is	 that	 although	 the	 start	 codon	 encodes	 a	
methionine,	 not	 all	 proteins	 begin	 with	 this	 amino	 acid.	 In	 about	 50%	 of	
polypeptides	 synthesised	 this	 methionine	 is	 removed	 by	 methionine	
aminopeptidase	(metAP	[Liao	et	al.	2004]).	
What	is	the	difference	between	this	canonical	protein	synthesis	according	to	the	




Programmed	 ribosomal	 frameshifting	 (PRF)	 mechanisms	 are	 genetically	
encoded	elements	within	an	RNA	found	now	rarely	 in	a	multitude	of	biological	
systems.	 It	 allows	 organism	 to	 fine	 tune	 control	 levels	 of	 certain	 proteins.	 In	
most	 cases,	 the	 frameshifting	 element	 occurs	 between	 two	 overlapping	 genes,	
with	 the	 second	 gene	 in	 a	 different	 frame	 from	 the	 first.	 As	 the	 ribosome	








need	 for	 a	 second	 promoter	 region	 or	 binding	 domain	 (Dinman,	 2006).	 The	
second	 is	 the	 fine	protein	balance	 that	can	be	attained	without	 the	need	 for	an	
additional	mechanism	or	pathway	to	modify	the	protein	post-translationally.	The	
first	 discovery	 of	 such	 a	mechanism	 occurred	 in	 the	 same	 laboratory	 that	 this	
research	was	based.	Craigen	et	al.	(1985)	discovered	a	novel	mechanism	of	gene	
regulation	 in	 bacteria	 that	 utilised	 programmed	 translational	 +1	 frameshifting	
(forward)	 to	 control	 the	 expression	 of	 release	 factor	 2	 during	 its	 synthesis	 in	
Escherichia	coli.	In	this	example	the	synthesis	is	terminated	after	25	amino	acids	
have	 been	 added	 unless	 frameshifting	 occurs	 when	 the	 full	 length	 protein	 is	
synthesised	(Craigen	et	al.	1986)		Unlike	the	backward(-1)	frameshifting		seen	in	
HIV-1,	 in	 the	 prfB	 gene	 of	 E.coli,	 as	 the	 ribosome	 travels	 along	 the	 mRNA,	 a	
slippery	 codon	 and	 a	 Shine	 Dalgarno	 sequence	 that	 interacts	 with	 the	 small	
subunit	rRNA	to	stall	translation	and	together	with	a		weak	stop	signal	the	pause		
causes	it	to	slide	forward	one	nucleotide.	Where	there	was	once	a	UGAC	(TGAC)	



















their	 virion	 size	 (Cui	 et	 al.	 2014).	 These	 authors	 discuss	 that	 the	 relationship	







The	 first	 instance	 of	 programmed	 ribosomal	 frameshifting	 within	 viruses	 was	
discovered	by	Jacks	and	Varmus	(1985)	a	few	months	after	the	initial	discovery	
of	 the	mechanism.	They	 found	 that	 translational	 frameshifting	occurred	within	
the	Rous	sarcoma	virus’	 (RSV)	 lifecycle.	However,	unlike	 in	E.coli,	 the	viral	RNA	
was	shown	to	shift	backwards	during	translation	by	one	nucleotide	(-1).	As	with	
most	 examples	 now	 known	 of	 (-1)	 ribosomal	 frameshifting	 the	 RSV	
frameshifting	region	contains	a	conserved	motif	with	three	elements.		
The	 first	 element	 is	 a	 so-called	 heptanucleotide	 “slippery	 sequence”.	 The	
sequence	 is	 not	 identical	 in	 each	 discovered	 example	 of	 the	motif,	 however	 it	




the	ribosome	slips	back	on	the	sequence	 it	becomes	thr-lys-phe	as	 the	event	 is	
thought	 to	 occur	 after	 the	 thr-tRNA	 enters	 the	 P	 site	 and	 therefore	 will	 be	
included	 in	 the	 sequence.	 However	 as	 shown	 by	 Cardno	 in	 HIV	 (2015),	 the	
frameshifting	event	can	occur	at	multiple	sites	along	the	slippery	sequence.	If	the	
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tRNA	 anti-codons	 in	 RSV	 are	 taken	 into	 account	 the	 accommodation	 of	 an	
adenine	 as	 the	wobble	base	of	 the	 asparagine	 tRNA	would	be	much	 less	 likely	
than	 the	 next	 option	 of	 a	 uracil	 in	 the	 leucine	 tRNA.	 This	 second	 possible	
frameshifting	 location	 is	more	 likely	 to	occur	due	to	the	physical	constraints	of	
the	 tRNA-codon	 interaction,	 where	 a	 larger	 purine	 is	 not	 likely	 to	 be	
accommodated	in	a	docking	position	intended	for	a	pyrimidine.			
The	 second	 element	 is	 a	 downstream	 secondary	 structural	 element	 caused	 by	
the	RNA	 sequence	 folding	 and	 forming	 intra	RNA	base	 pairs.	 It	was	 shown	by	
Marczinke	 (1998)	 that	 in	RSV	 the	 structure	was	 a	 pseudoknot	 rather	 than	 the	
stem-loop	structure	 seen	 in	HIV-1.	Unlike	 the	 slippery	sequence	 the	 sequences	
within	this	structure	do	not	often	directly	interact	with	tRNA	binding	or	the	EPA	
sites	 until	 after	 frameshifting	 has	 occurred.	 The	 importance	 of	 the	 secondary	
structure	 is	 linked	 to	 it	 having	 to	 be	 unwound	 to	 enter	 the	 ribosomal	 mRNA	
channel.	As	 the	ribosome	reaches	 the	slippery	sequence	 the	magic	of	evolution	
has	placed	the	secondary	structural	element	as	a	 large	and	difficult	to	 linearize	
region	of	 the	RNA.	As	 this	 region	 comes	 into	 contact	with	 the	entry	 site	of	 the	
ribosome	 it	 hinders	 the	 rate	 of	movement	 and	 translation	 and	 causes	 a	pause.	
Tension	 is	 caused	 as	 the	 ribosome	 attempts	 to	 ratchet	 along	 the	 RNA,	 and	
eventually	 this	 tension	causes	 the	 ribosome	 to	slip	back	on	 the	RNA	 in	a	 small	




region	 encodes	 for	 the	 viral	 polymerase,	 protease	 and	 integrase.	When	 in	 the	
normal	 reading	 frame	 the	 ribosome	 translates	 the	gag	 gene	 to	produce	 a	near	
functional	protein,	however	in	the	event	of	frameshifting	the	resulting	protein	is	
the	gag-pol	polyprotein	which	requires	modification	and	cleavage	as	previously	
described.	 As	 well	 as	 the	 mechanism	 being	 slightly	 different	 in	 respect	 to	
direction,	when	 compared	with	RF2	 in	E.coli,	 the	 event	 occurs	 less	 frequently;	
with	 the	 main	 product	 is	 ORF1	 rather	 than	 the	 ORF1-ORF2	 fusion.	 Jacks	 and	
Varmus	 (1985)	 showed	using	polyacrylamide	 gels	 that	 the	 translation	product	
levels	 were	 20:1	 in	 favour	 of	 the	 gag	 product,	 therefore	 indicating	 that	 the	
frameshift	 event	only	occurred	 in	5%	of	 translation	events.	The	 consistency	of	
	 23	





1988	 paper	 to	 account	 for	 the	 gag-pol	 proteins	 arising	 from	 two	 different	
reading	 frames.	This	 followed	 the	 initial	discovery	 from	 this	 research	group	of	
the	mechanism	of	 translational	 frameshifting	 in	1985	(Craigen	et	al.	1985)	and	
the	reporting	 that	a	 fusion	protein	between	 two	 frames	 in	RSV	might	not	have	
arisen	 from	differential	splicing	of	 the	RNA	transcript	as	originally	 thought	but	
also	by	a	translational	backwards	(-1)	frameshifting	mechanism.	However,	it	was	
not	 until	 1995	 through	 mutating	 the	 slippery	 sequence	 that	 Horsfield	 et	 al.	
confirmed	 the	 mechanism,	 albeit	 on	 prokaryotic	 ribosomes.	 This	 discovery	
opened	a	possible	vulnerable	site	in	the	biology	of	HIV-1	and	a	very	exciting	new	
pathway	by	which	HIV-1	could	be	targeted	for	antiretroviral	therapy.	As	shown	
by	 structural	 analysis	 and	 sequence	 alignment	 the	 core	 region	 containing	 the	
frameshift	 region	 is	highly	conserved	across	all	 isolates	and	subtypes	of	HIV-1,	
indicating	that	 the	region	 is	extremely	 important	 to	viral	 fitness	(Mathew	et	al.	
2015,	Sükösd	et	al.	2015).		
Programmed	 ribosomal	 frameshifting	 is	 especially	 important	 in	 HIV-1	 as	 it	
tightly	 regulates	 the	 relative	 amounts	 of	 the	 proteins	 generated	 from	 the	
encoded	 gag-pol	 complex.	 Without	 a	 frameshift	 event	 the	 ribosome	 would	
disengage	from	the	RNA	after	the	gag	gene	had	been	translated,	however	since		-
1	PRF	occurs	at	a	tightly	conserved	efficiency	of	5-10%	(Mathew	et	al.	2015)	only	




As	 with	 all	 eukaryotic	 -1	 frameshift	 elements	 discovered	 so	 far	 the	 HIV-1	
element	has	the	same	basic	structure;	with	the	slippery	sequence	complying	to	a	
(NN)	X	XXY	YYZ	0	frame	motif.	However,	in	HIV	compared	with	other	examples	















Using	 mass	 tandem	 spectrometry	 the	 translated	 peptides	 were	 observed,	 showing	 that	 the	








within	the	HIV-1	element	and	consequently	 the	variations	 in	sequence	of	 the	X	
XXY	YYZ	motif	might	not	have	the	importance	first	thought.	Later,	I	will	discuss	
the	 PEG10	 frameshift	 element,	which	 despite	 appearing	more	 difficult	 to	 slide	
back	 on	 has	 approximately	 a	 3-fold	 higher	 frameshift	 efficiency	 (Cardno	 et	 al.	
2015).		
The	 nature	 of	 the	 secondary	 structural	 element	 in	 HIV-1	 is	 surprising	 as	 it	 is	








that	 only	 the	 25	 nucleotides	 upstream	 from	 the	 secondary	 sequence	 was	
necessary	to	obtain	a	5-10%	frameshift	efficiency.		
A	 third	 element	 frameshift	 ‘sub-element’	 has	 been	 uncovered	 in	 HIV-1.	 This	
highly	 conserved,	 three-nucleotide	 stretch	 in	 the	 0	 frame	 is	 immediately	
proximal	 to	 the	 slippery	 sequence,	 and	has	been	named	 the	 intercodon	by	 the	
Tate	group.	The	dominant	intercodon	in	natural	isolates	of	HIV-1	are	the	glycine	
codons,	GGG,	(95%)	and,	GGA,	 	(3%)	recognised	by	the	same	tRNA.	(Mathew	et	
al.	 2014).	 As	 well	 the	 intercodon	 is	 conserved	 among	 many	 other	 retroviral	
species	 (Baranov	et	al.	2005).	Mathew	et	al.	 also	showed	 that	 if	 the	 intercodon	
was	 replaced	 by	 a	 stop	 codon,	 the	 frameshift	 efficiency	 vastly	 decreased,	 and	














in	 2001	 Shigemoto	 et	 al.	 discovered	 the	 first	 mammalian	 gene	 utilising	 -1	
frameshifting	 in	 a	 mammalian	 system	 in	 a	 mouse	 cancer	 cell	 line:	 the	 mouse	
embryonal	carcinoma	differentiation	regulated	(Edr)	gene.	
Although	 not	 completely	 orthologous	 to	 the	 HIV-1	 frameshift	 sequence	 the	
region	contained	the	same	generic	motif,	a	slippery	sequence	of	GGGAAAC,	which	
follows	 the	 XXXYYYZ	 format	 (Manktelow,	 2005),	 and	 then	 a	 proposed	
pseudoknot	 five	nucleotides	downstream	from	the	slippery	sequence	 (Namy	et	
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al.	 2004).	 As	 in	 HIV-1	 the	 frameshift	 region	 separated	 two	 overlapping	 open	
reading	 frames	(ORFs).	ORF1	encoded	a	CCHC	zinc-binding	domain,	which	was	
shown	to	have	a	high	content	of	basic	amino	acids	commonly	found	in	retroviral	




into	RNA	 in	 a	 highly	 restricted	manner	 throughout	 the	mouse,	 but	 include	 the	
adult	brain	and	ovary,	as	well	as	higher	expression	in	foetal	tissues	(Kikuno	et	al.	
1999),	 and	 are	 said	 to	 be,	 “essential	 for	 embryonic	 development	 in	 mice”	
(Manktelow	 et	 al	 2005).	 Most	 tissues	 expressing	 some	 RNA	 do	 not	 seem	 to	
synthesise	 the	 ORF1	 or	 ORF1-ORF2	 proteins	 as	 described	 below,	 with	 the	
exception	of	placenta,	amniotic	tissues,	brain	and	adrenals	(Shimaki,	PhD	thesis	
2015).	
Fascinatingly,	 with	 a	 seemingly	 ‘less	 slippery’	 sequence	 and	 only	 a	 proposed	
secondary	 structural	 element,	 the	 in	 vitro	 frameshift	 efficiency	 is	 >20%,	 in	
cultured	cells	(Shimaki	2015)	and	>	60%	in	mouse	placenta	which	is	many	fold	




HIV-1	 biology.	 Since	 -1	 frameshifting	 is	 no	 longer	 only	 observed	 in	 viridae,	
detailed	research	into	other	human	genes	with	possible	frameshifting	elements	
must	be	carried	out	before	any	human	trials	can	take	place.		
Paternally	 expressed	 gene	 10	 (PEG10)	 is	 a	 single	 copy	 gene,	 located	 on	
chromosome	7p21	(Lux	et	al.	2010).	Much	like	the	HIV-1	and	Edr	genes,	the	gene	
is	 composed	 of	 two	 open	 reading	 frames,	 named	 ORF1	 and	 ORF2	 (Ono	 et	 al.	
2001).	The	 structure	of	ORF1	has	been	determined	as	highly	 similar	 to	 that	of	
retroviruses,	sharing	the	“major	homology	region”	and	a	CCHC	zinc	finger	(Clark	






placenta	 in	 the	 later	 stages	 of	 pregnancy.	 This	may	 indicate	 that	 the	mRNA	 is	
activated	 for	 translation	 when	 placental	 development	 is	 occurring.	 If	 the	
frameshifting	 only	 occurs	 under	 these	 conditions,	 any	 adverse	 effects	 of	 drug	
compounds	 against	 HIV-1	 on	 the	 frameshift	 efficiency	 of	 PEG10	 would	 be	
nullified	with	the	use	of	a	contraceptive.		
The	sequence	motif	of	the	PEG10	frameshift	element	follows	the	classic	pattern	




al.	 2007).	 One	 hypothesis	 for	 the	 higher	 efficiency	 results	 from	 the	 secondary	
structural	 element.	 The	 PEG10	 pseudoknot	 is	 much	 larger	 and	more	 complex	
than	 that	 of	 the	HIV-1	 secondary	 structure,	making	 its	 impact	when	 it	 reaches	
the	 ribosome	 larger.	 The	 size	 difference	 is	 further	 exacerbated,	when	 the	 new	
model	of	frameshifting	is	taken	into	account.	Mathew	et	al.	(2015)	proposed	that	
the	intercodon	was	in	the	A	site	as	frameshifting	occurs.	In	PEG10	the	secondary	





The	 Ma/Pnma	 genes	 are	 a	 family	 of	 human	 genes	 thought	 to	 be	 of	 retroviral	
origin	(Wills	et	al.	2006),	as	the	structure	is	similar	to	that	of	PEG10.	The	family	
of	15	known	genes	are	 located	on	 the	X-chromosome	and	represent	a	range	of	
functions	 including	 pro-apoptotic	 pathways	 (Schüller	 et	al.	 2005).	 Some	 of	 the	







the	 genes	 may	 simply	 be	 a	 relic	 of	 functional	 ancestral	 genes	 or	 retroviral	
insertions.	 Unlike	 PEG10	 these	 proteins	 have	 only	 been	 observed	 in	vitro,	 and	




The	 most	 recent	 and	 second	 credible	 human	 gene	 with	 a	 -1	 frameshifting	
element	was	observed	in	the	gene	for	C-C	chemokine	receptor	5	(CCR5,	[Belew	et	
al.	 2014]).	 The	 CCR5	 gene	 encodes	 for	 a	 seven-transmembrane	 G	 protein-
coupled	receptor,	the	protein	regulates	trafficking	as	well	as	regulating	effector	
functions	 of	 immune	 cells	 (Oppermann,	 2004).	 One	 interesting	 feature	 of	 this	




slip	 into	 the	 second	 information-rich	 open	 reading	 frame,	 when	 frameshifting	
occurs	a	premature	stop	codon	is	reached	and	the	resulting	unstable	protein	 is	
degraded.	Whereas	the	other	systems	use	the	mechanism	to	regulate	the	balance	
between	 the	 two	 encoded	 genes,	 CCR5	 uses	 the	 region	 to	 tightly	 regulate	 the	
expression	of	one	gene	using	this	novel	mechanism.	Using	a	dual	luciferase	assay	
Belew	 et	al.	 (2014)	 determined	 the	 frameshift	 efficiency	 to	 be	 9-11%	 in	 HeLa	
cells	 and	 4.5%-6.3%	 in	 Chinese	 hamster	 ovary	 cells.	 The	 similarity	 between	
these	values	and	that	of	HIV-1,	suggested	that	the	slippery	sequence	(UUUAAAA),	
which	 is	 similar	 to	 the	 UUUUUUA	 HIV-1	 sequence	 may	 dictate	 the	 frameshift	
efficiency.	 To	 further	 validate	 this	 hypothesis,	 the	 sequence	 was	 mutated	 to	
GCGCGCG,	 so	 that	 re	 pairing	 of	 the	 tRNAs	 could	 not	 occur	 in	 the	 new	 frame	
therefore	completely	destroying	 the	efficacy	of	 the	sub-element.	The	mutations	
decreased	the	frameshift	efficiency	to	<1%,	a	dramatic	decrease.	As	well	the	high	




Although	 CCR5	 fits	 the	 classic	 -1PRF	 element	 the	 proposed	 mechanism	 of	
frameshift	 regulation	 is	 vastly	 different	 to	 that	 observed	 in	 HIV-1	 and	 PEG10.	
Unlike	previously	described	mechanisms,	and	although	the	putative	pseudoknot	
is	much	larger	than	the	SSE	of	HIV-1	or	PEG10,	regulation	of	PRF	is	mediated	by	




Interestingly,	 HIV-1	 was	 used	 as	 a	 control	 and	 had	 the	 expected	 frameshift	
efficiency	in	HeLa	cells,	but	when	siRNAs	against	Argonaute	were	transfected	the	
frameshift	efficiency	the	CCR5	element	decreased	but	increased	with	that	of	HIV-




distinct	 possibility	 that	 Argonaute	might	 be	 the	 reason	HIV-1	 shows	 such	 low	
frameshift	 efficiency	 when	 compared	 with	 other	 -1PRF	 elements.	 The	 results	
indicate	 a	 possible	 siRNA	 blocking	 ability	 due	 to	 this	 binding	 of	 Argonaute	 by	





While	 -1PRF	 offers	 a	 novel	 mechanism	 to	 target,	 and	 could	 potentially	 avoid	
many	 of	 the	 side	 effects	 seen	 in	 current	 treatments,	 due	 to	 the	 presence	 of	
similar	mechanisms	within	mammalian	systems,	potential	off-target	effects	may	
also	occur.	Understanding	the	mechanism	by	which	frameshifting	occurs	within	








heptamer,	 slippery	 sequence	 (Moon	 et	al.	 2004).	 In	HIV-1	 this	 sequence	 has	 a	
uracil	rich	region	which	when	read	by	the	ribosome	is	susceptible	to	misreading	
causing	a	-1	frameshift	in	the	reading	frame	(Kim	et	al.	2014).	Although	over	the	
years	 many	 mechanisms	 for	 frameshifting	 have	 been	 proposed,	 a	 favoured	
mechanism	 for	 this	 misreading	 event	 is	 translational	 pausing,	 caused	 by	 the	




25	 nucleotide	 experiment	 seen	 in	 Wilson	 et	 al.	 (1988),	 where	 loss	 of	 the	




that	 are	 very	 similar	 regardless	 of	 the	 differing	 size	 and	 structures	 of	 their	










models,	 it	 claims	 that	 the	 downstream	 SSE	 causes	 tension	 on	 the	mRNA	 as	 it	
enters	 the	ribosome	causing	pressure	on	 the	 tRNA	and	ribosome	binding	sites,	
allowing	the	mRNA	to	spring	back	one	nucleotide	and	change	the	reading	frame.	
This	 proposed	mechanism	 relies	 on	 the	 premise	 of	 the	 occurrence	 of	 a	 hybrid	
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state	 in	 the	 ribosome	 entry	 (T)	 and	 A	 sites	 during	 peptidyl-transfer,	 after	 the	
tRNA	has	entered	the	ribosome	but	before	 translocation	of	 the	 tRNA	has	 taken	
place.		As	the	tRNA	anticodon	binds	to	the	mRNA	codon	representing	the	5th-7th	
nucleotides	of	the	slippery	sequence	the	peptidyl	end	of	the	tRNA	occupies	the	T	
site	whilst	 the	anticodon	occupies	 the	A	 site,	 forming	 the	A/T	hybrid	 state.	 	 In	
this	model	the	threshold	of	energy	required	for	the	un-pairing	and	re-pairing	of	
the	bound	tRNAs	is	thought	to	be	decreased	by	the	hydrolysis	of	GTP	to	GDP	via	
eEF1A	 action.	 This	 was	 validated	 through	 mutational	 studies,	 where	 eEF1A	
mutants	affected	but	did	not	nullify	the	rate	of	frameshift,	therefore	indicating	a	










enough	tension	to	make	the	tRNA	switch	 from	the	A/T	hybrid	state	 to	 the	A/A	
state.	
The	major	 flaw	 in	 this	proposed	mechanism	 for	 this	model	 is	 that	 it	hinges	on	
ribosomal	pausing	caused	by	slow	rates	of	peptide	transfer	(Atkins	&	Gesteland,	
2010).	 However	 the	 peptide	 transfer	 rate	 is	 proposed	 to	 be	 faster	 than	 tRNA	




formation	 and	 possibly	 peptidyl	 transfer	 is	 likely	 to	 have	 occurred	 before	 the	
tRNA	 has	 bound,	 therefore	 the	 timeline	 this	 model	 follows	 is	 most	 probably	




the	P	and	A	sites,	 the	 linker	or	 intercodon	region	is	 in	the	mRNA	tunnel	on	the	
ribosome	 (Plant	 et	 al.	 2003).	 However	 more	 recent	 studies	 have	 shown	 a	





The	 simultaneous	 slippage	model	 was	 the	 first	 model	 proposed	 for	 -1PRF,	 by	
Jacks	 et	 al.	 (1988).	 However	 due	 to	 the	 limited	 experimental	 techniques	
available,	 and	 primitive	 understanding	 of	 ribosomal	 protein	 synthesis	 at	 that	
time,	coupled	with	the	paper’s	proximity	to	the	discovery	of	HIV-1	frameshifting	
(by	the	same	lab),	the	scientific	precision	underpinning	this	hypothesis	is	not	as	
strong	 as	 with	 later	 models.	 It	 dictates	 that	 slippage	 takes	 place	 before	 the	
peptidyl	 transfer	 and	 after	 the	 accommodation	 of	 the	 tRNA	 into	 the	 A	 site	
(Brierley	et	al.	2010).	Unlike	other	models	this	accounts	for	both	tRNAs	present	
in	 the	 P	 and	 A	 sites	 with	 the	 name	 of	 the	method	 indicating	 that	 both	 tRNAs	
detaching	 and	 slipping	 back	 at	 the	 same	 time	 (Atkins	 &	 Gesteland,	 2010).	
However,	the	method	fails	to	explain	the	driving	force	behind	tRNA	movement.	
As	with	 any	physical	 system	energy	 is	 required	 to	detach	 and	pair	 tRNAs,	 and	





Another distinctly different model is the dynamic model, first described by Weiss et 
al. (1989). This model also involves a hybrid-state, however in the dynamic model the 
two tRNAs occupy the hybrid E/P and P/A sites after accommodation. The presence 
of the tRNAs in the hybrid sites is hypothesised to destabilise the P site hydrogen 
bonds and promote frameshifting (Atkins	&	Gesteland,	2010).  In more recent years, 
Giedroc and Cornish (2009) added validation to the model, showing (using cryo-
electron microscopy [cryo-EM]) the mammalian 60S subunit translocates with hybrid 
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states, before 40S translocation reinstates the usual ribosomal confirmation. This 
experiment showed the ability for the tRNAs to enter the hybrid state but did not 
prove that this occurs during every frameshift event. As for the timing of the model, 
the -1 frameshift may occur before or after the 40S translocation event the energy 
required to dissociate the tRNA during the elongation cycle is created by the 
movement of the 60S subunit. Due to the first slippery sequence codons being in the 
E site, the intercodon would be in the A site rather than in the ribosomal mRNA 
channel as described in the integrated model. This distinct feature causes a large 
difference between the models and causes the dynamic model to be the more likely of 
the two when Mathew’s possible intercodon interaction is taken into account (Mathew 





which	 require	 input	 of	 energy	 to	 break	 the	 tRNA	 anticodons’	 H	 bonds,	 the	
mechanical	 model	 is	 force-based.	 	 Protein	 purification	 and	 cryoelectron	
microscopy	 (cryo-EM)	was	 used	 to	 visualise	 the	 80S	 ribosome	 translating	 the	
mRNA	at	the	molecular	level.	Their	theory	was	that	when	the	pseudoknot	came	
into	contact	with	the	ribosome	during	translation,	a	mixture	of	steric	hindrance	
and	difficulty	 in	dissolving	 the	structure.	 	The	RNA	sequence	caused	stalling	of	
the	 small	 ribosomal	 subunit	 whilst	 eEF2	 was	 still	 bound.	 To	 validate	 this	
hypothesis	 they	 created	 a	 native	 pseudoknot	 construct	 and	 captured	 the	




allowing	 the	 tRNA	 to	 move	 in	 the	 negative	 direction	 and	 re-engage	 one	
nucleotide	upstream	in	the	-1	frame.	To	prove	that	the	tension	itself	was	able	to	
create	 enough	 force	 to	 break	 the	 codon-anticodon	 bonds,	 Namy	 deleted	 the	
pseudoknot	 and	 replaced	 it	 with	 single	 stem	 loop.	 The	 resulting	 interaction	
between	it	and	the	ribosome	was	such	that	it	was	able	to	stall	ribosome	but	not	
effectively	 promote	 efficient	 frameshifting.	 Indicating	 with	 a	 longer	 ribosomal	
	 34	
stalling	time,	the	probability	of	a	frameshift	event	increases.	However	this	theory	
does	 not	 account	 for	 the	 findings	 of	Wilson	 et	 al.	 (1988)	when	 a	minimal	 25-
nucleotide	 sequence	 is	 sufficient	 to	 promote	 frameshifting	 with	 efficiency	
equivalent	to	that	of	the	native	HIV-1	system.	This	model	does	however	require	
the	intercodon	to	come	into	contact	with	the	ribosome,	as	due	to	the	necessary	
interaction	 between	 it	 and	 the	 secondary	 structural	 element,	 the	 intercodon	
would	 need	 to	 be	 within	 the	 mRNA	 tunnel	 for	 the	 required	 proximity	 of	 the	
ribosome	 and	 SSE.	 This	 model	 may	 prove	 to	 be	 adequate	 model	 to	 explain	




The	 most	 recent	 peer	 reviewed	 model	 is	 the	 three-tRNA	 model,	 proposed	 by	
Farabaugh	et	al.	(1997)	and	experimentally	supported	by	Léger	et	al.	(2007).	The	
major	 difference	 between	 this	 model	 and	 those	 previously	 mentioned	 is	 the	
presence	 of	 a	 bound	 tRNA	 in	 the	 E	 site	 of	 the	 ribosome.	 The	 model	 shares	 a	
similarity	 with	 the	 dynamic	 model	 as	 the	 during	 the	 frameshifting	 event	 the	
tRNAs	 are	 in	 a	 two-site	 hybrid	 state,	 with	 tRNAs	 occupying	 the	 E/P	 and	 P/A	
sites.	As	during	 this	 time	 the	slippery	sequence	occupies	 the	A	and	P	sites,	 the	
movement	of	the	tRNAs	causes	tension	on	the	mRNA	in	the	positive	direction.	It	
is	thought	this	pulls	the	bound	slippery	sequence	into	the	E	and	P	sites,	however	
due	 to	 interaction	 between	 the	 ribosome	 and	 the	 SSE,	 the	 movement	 of	 the	
mRNA	is	limited	to	two	bases	causing	a	disruption	in	the	codon-anticodon	bonds.	
When	 a	 new	 tRNA	 enters	 the	 A/T	 site,	 it	 causes	 the	 tRNAs	 to	 reattach	
sequentially,	 however	 due	 to	 the	 position	 of	 the	mRNA	 relative	 to	 the	 hybrid	
tRNAs,	 they	 bind	 in	 the	 -1	 frame.	 The	 event	 itself	 is	 thought	 to	 occur	 before	
peptide	 transfer	 or	 binding	of	 the	 tRNA	 in	 the	A/T	 site.	 This	 is	 the	 first	 of	 the	
proposed	models	to	involve	the	presence	of	a	tRNA	in	the	E	site,	indicating	that	
the	slippery	sequence	is	further	into	the	ribosome	than	in	previously	described	
models.	 If	 applied	 to	 Mathew’s	 intercodon	 interaction	 hypothesis,	 there	 is	 a	
possibility	 that	 the	 slippery	 sequence	 occupies	 the	 E	 site	 with	 its	 2nd-4th	
nucleotides	 rather	 than	 the	1st	 as	described	by	Léger	et	al.	 (2007).	This	would	
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allow	the	 intercodon	to	occupy	 the	A/T	hybrid	site	and	 therefore	 interact	with	
the	 ribosome.	 The	model	 also	 refers	 to	 the	 secondary	 structural	 element	 as	 a	
stimulatory	signal,	indicating	that	the	tension	required	by	the	mechanical	model	




















the	 observed	 conserved	 sequence	 is	 essential	 for	 frameshift	 efficiency	 that	
supports	 viable	 HIV-1	 replication.	 As	 the	 function	 of	 this	 gene	 element	 is	 to	
provide	tight	regulation	of	protein	synthesis	in	a	system	attempting	to	avoid	host	








to	 8-fold	 reduction	 in	 the	 efficiency	 resulted	 in	 a	modest	 or	 severe	 replication	
defect	and	any	further	reduction	abolished	replication	entirely,	whereas	when	a	
stimulator	was	used	a	3-fold	increase	in	frameshifting	was	enough	to	render	the	
virus	 unable	 to	 replicate.	 If	 the	 mechanism	 between	 RSV	 and	 HIV-1	 are	





compound	 is	 PEG10.	 Kaneko-Ishino	 &	 Ishino	 (2013)	 showed	 the	 gene	 is	
important	 in	 the	 development	 and	 maintenance	 of	 the	 placenta	 in	 mammals.	





(Ono	 et	 al.	 2006).	 This	 indicates	 that	 any	 modulation	 of	 the	 PEG10	 protein	
products	 could	 cause	 serious	 complications	 in	 pregnancy.	 	 However	 as	 with	
many	prescription	medications	available,	such	as	those	containing	retinoic	acid,	
if	 the	 only	 complications	would	 result	 during	 pregnancy	 an	 oral	 contraceptive	
could	be	used	to	avoid	ovulation,	pregnancy	and	the	expression	of	PEG10.	
It	is	known	that	the	mechanism	for	PEG10	frameshifting	is	caused	by	tension	due	
to	 its	 large	 secondary	 structural	 element.	 It	 has	 been	 shown	 with	 siRNA	
knockdown	 in	 B-CLL	 and	 HepG2	 tumour	 cells,	 that	 an	 observed	 50-90%	
knockdown	 of	 normal	 PEG10	 protein	 expression	 (2-12%	 overall	 frameshift	
efficiency)	 did	 not	 effect	 cell	 survival	 (Kainz	 et	 al.	 2007).	 This	 observed	
knockdown	 corresponds	 with	 the	 values	 seen	 needed	 in	 RSV	 for	 the	 effective	
inhibition	of	infectivity	(Nikolić	et	al.	2012).	Therefore	if	the	compound	has	the	
same	dose-effect	on	both	PEG10	and	HIV-1	the	negative	effects	of	PEG10	would	
be	 minimal.	 However,	 Kainz	 et	 al.	 detected	 apoptosis	 and	 a	 change	 in	 the	




Luckily	 the	 compounds	 used	 thus	 far	 in	 development	 of	 a	 small	 molecule	







co-receptor	 for	 R-5	 strains	 of	 HIV-1	 in	 most	 of	 the	 early	 strains	 (Wyatt	 &	
Sodroski,	 1998).	 This	 gives	 rise	 to	 the	 possibility	 that	 if	 a	 drug	 that	 affects	







rather	 a	 complete	 lack	 of	 protein	 that	 decreased	 receptor	 number	 on	 the	 cell	
membrane.	 It	 has	 been	 shown	 that	 binding	 inhibition	 of	 the	 CCR5	 co-receptor	
significantly	 lowers	 the	 rate	 of	 HIV-1	 infection	 in	 Rhesus	 Macaque	 where	 an	




Stumpf,	 2004).	 This	 immunity	 occurs	 as	 the	mutation	 introduces	 a	 premature	
stop	 codon	 (much	 like	 the	 frameshifting	 product),	 which	 shortens	 the	 overall	
peptide	 structure	 and	 leads	 to	 a	 protein	 unable	 to	migrate	 to	 or	 span	 the	 cell	
membrane.	 Unfortunately,	 in	 addition	 to	 the	 benefits	 of	 decreased	 functional	
CCR5	 transmembrane	 proteins,	 there	 have	 been	 some	 hypothesised	 negative	
impacts	 to	 the	 host.	 It	 is	 thought	 CCR5	 mutation	 leads	 to	 an	 increased	
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susceptibility	 to	 some	 pathogens,	 and	 could	 also	 cause	 tissue	 injury	 due	 to	
postinfectious	 inflammatory	 response	 (Klein,	 2008).	 However	 in	 the	 case	 of	
possible	HIV-1	 infection	 the	 implication	of	 tissue	damage	 is	a	minor	side	effect	
when	compared	to	the	development	of	AIDS.	As	the	-1	frameshifting	in	CCR5	has	
been	shown	 to	 rely	heavily	on	miRNAs,	 the	developed	small	molecules	are	not	
expected	to	create	any	fluctuations	in	frameshifting	efficiency,	as	the	molecules	
are	thought	to	bind	specifically	to	the	stemloop	of	HIV-1	(Cardno	et	al.	2015).	It	
is	 therefore	 improbable	 that	 any	 modulatory	 activity	 will	 occur	 and	 any	




Since	 the	 first	 recognised	case	of	HIV/AIDS	 in	1981	 (Masur	et	al.),	 the	US	 food	
and	drug	administration	(FDA)	has	approved	only	25	drug	treatments	(AIDSinfo,	
2016).	Of	these	drugs	there	are	six	major	classes	that	target	varying	steps	of	the	




Due	 to	 the	 nature	 of	 drug	 development	 during	 the	 early	 stages	 of	 a	 disease	
outbreak	 (where	 speed	 of	 treatment	 is	 paramount),	 the	 first	 drugs	 tested	 are	





mechanism	 of	 action	 relies	 on	 the	 cellular	 enzymes	 to	 convert	 them	 into	 a	
triphosphate	 form.	 This	 allows	 the	 drugs	 to	 competitively	 bind	 to	 reverse	
transcriptase	 (RT)	 polymerase.	 Due	 to	 a	 lack	 of	 a	 3’-hydroxyl	 group,	 the	
compounds	stop	the	synthesis	of	DNA	within	the	host	cell,	therefore	stopping	the	
transcription	of	viral	DNA	(Maga	et	al.	2010).	Unfortunately,	as	the	binding	of	the	






HIV/AIDS,	 the	 high	 mutation	 rate	 of	 HIV-1	 often	 leads	 to	 bypassing	 of	 the	
pathway	and	therefore	reduced	viral	sensitivity.	




cannot	 mature	 proteins	 are	 not	 produced	 (Hughes	 et	 al.	 2011).	 This	 leaves	
immature	viral	proteins	unable	to	be	packaged	into	the	viral	capsid.		
There	are	 currently	 ten	FDA	approved	protease	 inhibitors	 for	 the	 treatment	of	
HIV-1.	The	first,	saquinavir	was	approved	for	use	in	1995.	However	within	a	year	
two	 genetic	 mutations	 in	 the	 viral	 protease	 had	 been	 documented	 (known	 as	




(NNRTIs).	 Nevirapine	 was	 approved	 by	 the	 FDA	 in	 1996	 (a	 subsequent	 three	
compounds	 have	 been	 approved),	 NNRTIs	 were	 developed	 to	 directly	 replace	
the	failing	NRTIs.	They	did	this	by	binding	to	a	separate	site	to	NRTIs	(exclusive	
of	 the	active	site).	NNRTIs	bind	a	hydrophobic	pocket	approximately	10Å	 from	
the	 polymerase	 active	 site.	 Due	 to	 the	molecular	 structure	 of	 the	 polymerase,	
when	NNRTIs	are	absent	the	binding	pocket	does	not	exist	and	the	polymerase	
will	 work	 perfectly	 normally.	 With	 the	 NNRTIs	 present	 however	 the	 pocket	
opens	up	allowing	the	compound	to	bind.	It	is	thought	that	in	doing	this	the	drug	
changes	 the	 structural	 confirmation	 around	 the	 polymerase	 active	 site,	
rendering	it	unable	to	bind	the	HIV-1	genome	(Schauer	et	al.	2014).	However	as	
with	 NRTIs	 single	 amino	 acid	 mutations	 in	 the	 binding	 pocket	 gave	 rise	 to	
resistance	 against	 the	 compounds	 (de	 Béthune,	 2010).	 It	 is	 thought	 that	
mutation	 of	 the	 pocket	 does	 not	 necessarily	 stop	 the	 binding	 of	 the	 drug	
compound,	but	the	mutation	stops	the	allosteric	inhibition.	
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Fusion/Entry	 inhibitors	 block	 the	 entry	 of	 HIV-1	 into	 the	 cell	 by	 one	 of	 two	
mechanisms:	fusion	inhibitors	such	as	enfuvirtide	(FDA	approved	2003)	bind	to	
the	 host	 cell	 gp41	 transmembrane	 protein	 therefore	 stopping	 the	 virion	 from	
fusing	 to	 the	 cell	 membrane	 and	 entering	 the	 cell	 (Lalezari	 et	 al.	 2003).	
Unfortunately	 mutations	 in	 the	 HR1	 binding	 domain	 in	 viral	 gp41	 cause	 the	
enfuvirtide	to	no	longer	bind	the	viral	envelope	and	can	no	longer	inhibit	HIV-1	
from	 fusing	 to	 the	 cell	 membrane	 and	 entering	 the	 cell	 (Reeves	 et	 al.	 2005).	
Entry	 inhibitors	 like	 miraviroc	 (FDA	 approved	 2007)	 modify	 the	 CCR5	
extracellular	 loops,	 causing	 the	 virion	 to	 no	 longer	 recognise	 it.	 Resistance	
against	entry	inhibitors	occurs	with	evolution	of	the	gp120	glycoprotein	on	the	
viral	envelope.	By	changing	the	phenotype	of	this	glycoprotein,	the	virus	is	able	
to	 recognise	 and	 bind	 the	mutated	 CCR5	 leading	 to	 cell	 infection	 (Roche	 et	al.	
2013).	
Integrase	 inhibitors	 make	 up	 the	 final	 class	 of	 true,	 FDA	 approved,	 HIV-1	




the	 integrase	 active	 site.	 By	 binding	 this	 area	 the	 inhibitor	 is	 able	 to	 directly	
block	interaction	between	the	integrase	metal	ions	and	the	host	DNA	phosphate	
group	 (Mouscadet	&	Tchertanov,	 2009).	 As	 the	 target	 of	 the	 treatment	 is	 viral	
integrase	it	is	more	specific	than	other	potential	treatment	options.	However,	by	
the	 time	 it	 had	 entered	phase	 three	human	 trials	 some	patients	were	 showing	
reduced	sensitivity	to	the	drug	compounds	(Temesgen	&	Siraj,	2008).		
To	 improve	 the	 efficacy	 and	 lower	 the	 rate	 of	 resistance	 against	 compounds	
many	drugs	are	taken	in	combination,	as	it	is	more	difficult	to	gain	the	multiple	
mutations	 required	 to	 gain	 resistance	 to	 all	 drugs	 relevant	 to	 multiple	 drug	
pathways.	 In	 addition	 to	 this	 treatment	 strategy,	 the	 FDA	 has	 approved	 one	
pharmacokinetic	 enhancer:	 cobicistat	 boosts	 levels	 of	 given	 drugs	 in	 the	
bloodstream	 whilst	 keeping	 them	 below	 toxic	 levels,	 allowing	 faster	 more	
effective	treatment	(AIDSinfo,	2016).	
The	current	‘in	vogue’	prophylaxis	is	a	nucleotide	reverse	transcriptase	inhibitor	
(NtRTI)	 named	 tenofovir	 (World	 Health	 Org.	 2011).	 Trials	 using	 this	 gel	 as	 a	
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preventative	 measure	 have	 shown	 a	 39-54%	 decrease	 in	 HIV	 acquisition,	
dependent	 on	 gel	 adherence	 (Abdool	 Karim	 et	 al.	 2010).	 The	 drug	 may	 be	
showing	promise	now,	but	due	 the	similarities	between	NtRTIs	and	NRTIs	 it	 is	
likely	 that	 reduced	 sensitivity	 to	 the	 compounds	 will	 occur.	 Therefore	 a	




Since	 the	 frameshifting	 element	 is	 highly	 conserved	 across	 the	HIV-1	 subtypes	
(Sükösd	et	al.	2015)	it	is	an	ideal	candidate	for	the	targeted	treatment	of	HIV-1,	
however	due	to	the	presence	of	the	element	in	other	viruses,	any	drug	compound	
developed	may	 act	 as	 a	 treatment	 for	 other	 viral	 infections	 as	 well.	 One	 such	




Rich,	 2001).	 HTLV,	 much	 like	 HIV-1	 is	 transferred	 by	 blood-blood	 contact,	 by	
sexual	 interactions	 and	 via	 breastfeeding	 (Carneiro-Proietti	 et	al.	 2014).	 HTLV	
affects	15-20	million	people	worldwide	and	approximately	6.6%	develop	T-cell	
lymphoma	 in	 males	 and	 2.1%	 in	 females	 (Matsuoka	 &	 Jeang,	 2007).	 If	 a	
compound	 such	 as	 those	 discovered	 by	 Cardno	 (2015),	 could	 be	 used	 to	 treat	
HTLV	and	other	viruses	containing	a	programmed	frameshifting	region,	millions	
of	lives	could	be	saved.	













the	 contributions	 of	 each	 sub-element	 to	 frameshift	 efficiency	 within	 each	
system.		
(ii)	 cloning	 the	 sub-elements	 into	 the	 bicistronic	 fluorescence	 reporter	 system	
developed	by	Cardno	(2015).	
(iii)	 transfecting	 plasmids	 containing	 the	 cloned	 sub-elements	 into	 HEK293T	
cells	and	expressing	the	reporters	to	determine	frameshifting	efficiency	for	each	
of	the	constructs.	
(iv)	 cloning	 the	 CCR5	 element	 in	 the	 bicistronic	 vector	 and	 expressing	 	 in	
HEK293T	cells.		
(v)	determine	where	 the	discovered	enhancer	of	HIV	 -1	 frameshifting	binds	 in	






(vi)	 vectors	 containing	 the	 native	 sequence	 and	 those	 with	 a	 substituted	
secondary	structural	element	will	be	to	be	tested	in	human	cells.	To	validate	the	
results	from	this	analysis	







































TE	Buffer:	 	 	 	 	 20x	SB	Buffer:	
	 Tris	(pH	8.0)	 	 0.12	M		 	 NaCl	 	 	 8.0	g	
	 EDTA	 	 	 0.372	mM	 	 Boric	Acid	 	 ~50.0	g	
	 ddH2O	to		 	 1.0L	 	 	 ddH2O	to		 	 1.0	L	
	 	 	 	 	 	 	 Adjusted	to	pH	8.0	
	
10x	PBS:		
	 NaCl	 	 	 80	g	
	 KCl	 	 	 2	g	
	 Na2HPO4	 	 14.44	g	




TBE	Buffer:	 	 	 	 	 DNA	Loading	Buffer,	10x:	
	 Tris	 	 	 9	mM	 	 	 Sucrose		 	 20%	
(w/v)		
	 Boric	Acid	 	 5.5%	(w/v)	 	 Bromophenol	Blue		 0.5%	
(w/v)		
	 EDTA	 	 	 20	mM	 	 NaOH	 	 	 1	nM	
	 ddH2O	to		 	 1L	
	
Agarose	Gel,	3%:	
	 Agarose		 	 0.9	g	




PBS-EDTA:	 	 	 	 	 Freezing	Media	
Added	0.53	mM	EDTA	(pH	8.0)	to	PBS	 	 FCS	 	 	 90%	(v/v)	




LB	(Luria-Bertani)	media:	 	 	 Supplemental	antibiotics:	
	 Bacterial	Peptone	 10.0	g	 	 	 Ampicillin		 	 50	μg/mL	
	 Bacterial	Yeast	 5.0	g	 	 	 Kanamycin	 	 100μg/mL	
	 NaCl	 	 	 10.0	g	 	 	 Tetracyclin	 	 20	μg/mL	
	 ddH20	to		 	 1.0	L	
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	 	 	 	 	 	 SOB	(Super	Optimal	Media):	
LB	Plates:	 	 	 	 	 	 Tryptone	 	 10.0	g	
Agar	 	 15	g/L	to	LB	 	 	 	 Yeast	Extract	 	 5.0	g	
	 	 	 	 	 	 	 NaCl	 	 	 0.5	g	
	 	 	 	 	 	 	 ddH2O	to	 	 1.0	L	
	 	 	 	 	 	 	 250mM	KCl	 	 10	mL	






out	 using	 a	 Qiagen	 QIAprep	 Spin	 Miniprep	 Kit	 (Qiagen,	 Germany).	 Once	 the	
plasmid	was	deemed	correct	via	sequence	analysis	a	larger	isolation	of	DNA	was	
performed	with	a	Qiagen	Plasmid	Maxi	Kit.	Miniprep	kits	require	cells	grown	in	5	













For	 this	 study,	all	 sequencing	was	handled	by	Genome	Analysis	Services	 in	 the	
University	 of	 Otago	 Anatomy	 Department.	 As	 most	 of	 the	 constructs	 were	
formed	using	site	directed	mutagenesis,	they	only	had	small	nucleotide	changes	



















degree	 of	 accuracy	 during	 reactions.	 However,	 the	 site	 directed	 mutagenesis	
reaction	requires	a	much	higher	degree	of	accuracy	as	a	very	low	number	of	base	
pair	 changes.	 For	 this	 reason,	 Phusion	 Hot	 Start	 II	 High	 Fidelity	 Polymerase	
(Thermo	 Scientific,	 USA)	 as	 it	 has	 a	 50-fold	 lower	 error	 rate	 than	 seen	 in	Taq	
polymerase	reactions	(Thermo	Scientific,	2012).	
Site	 directed	 mutagenesis	 reactions	 were	 performed	 using	 the	 temperatures	
calculated	using	the	annealing	temperatures	of	the	overlapping	regions	and	the	
subsequent	 non-overlapping	 regions.	 This	 was	 created	 by	 designing	 a	
temperature	 difference	 of	 a	 minimum	 of	 10°C	 to	 ensure	 annealing	 of	 the	
overlapping	region	without	annealing	of	the	other.	When	using	Phusion	Hot	Start	
II,	 all	 temperatures	 were	 increased	 by	 3°C	 due	 to	 manufacturer’s	
recommendations	and	decreased	by	5°C	as	described	 for	efficient	 site	directed	
mutagenesis	by	Liu	&	Naismith	(2008).	
For	 constructs	with	 a	 high	GC	 content,	 such	 as	 PHP	 construct,	which	 has	 a	GC	
content	 of	 72.88%,	 the	 addition	 of	 3%	 dimethyl	 sulfoxide	 (DMSO)	 aided	 the	
reaction	as	at	high	concentrations,	it	has	been	shown	to	reduce	the	melting	point	
of	 nucleic	 acids	 (Chester	 &	 Marshak,	 1993).	 The	 addition	 of	 DMSO	 can	 also	
reduce	 the	 Tm	 too	 far	 and	 the	 annealing	 temperature	 has	 to	 be	 adjusted	 to	

























After	each	of	 the	PCR	reactions	 the	DNA	was	 treated	with	5	U	DpnI	before	a	2	
hour	 incubation	 at	 37°C.	 This	 enzyme	 cuts	 DNA	 at	 a	 methylated	 GATC	 site,	
meaning	that	digestion	of	DNA	will	only	occur	 in	the	methylated	template	DNA	
and	 not	 the	 newly	 created	 PCR	 product.	 This	 digestion	 ensures	 that	 if	 the	
mutations	 have	 been	 successfully	 carried	 out,	 the	 only	 DNA	 present	 in	 the	
sample	 is	 the	 DNA	 of	 interest	 and	 not	 the	 unmutated	 DNA.	 This	 therefore	





The	 DNA	 fragments	 and	 plasmids	 were	 separated	 on	 0.8%	 agarose	 gels	 via	
electrophoresis.	 The	 gels	were	made	using	 sodium	borate	 buffer	 and	1	 μg/mL	
ethidium	 bromide.	 Using	 a	 Bio-Rad	 Powerpac	 300	 (BioRad	 Laboratories	 Inc.	
USA),	each	gel	was	run	 for	approximately	50	minutes	at	180V,	or	until	 the	dye	










37°C	 for	 approximately	 8	 hours	 before	 being	 transferred	 to	 a	 culture	 flask	
containing	 500	 mL	 of	 SOB	 medium.	 The	 cells	 were	 then	 incubated	 overnight,	
shaking	at	200rpm	at	18°C	(New	Brunswick	Scientific	Co.	Inc,	USA).	The	sample	









10	 ng	 of	 plasmid	DNA	was	 transformed	 into	 100	 μL	 of	 DH5α	 competent	 cells.	
This	 was	 achieved	 by	 mixing	 each	 10ng	 plasmid	 DNA	 with	 DH5α	 cells	 and	







The	CCR5	natural	 and	 readthrough	 constructs	were	 created	by	 inserting	CCR5	
PCR	 products	 specific	 to	 the	 region	 of	 interest	 into	 the	 previously	 used	
bicistronic	 vector.	 To	 enable	 easy	 insertion	 of	 the	 desired	CCR5	 construct	 into	
vector	 the	 Gateway	 system	 was	 used.	 The	 initial	 BP	 reaction	 requires	 the	
addition	 of	 attB	 regions	 to	 both	 ends	 of	 the	 desired	 DNA	 construct	 using	 a	
polymerase	 chain	 reaction.	 The	 PCR	 product	 is	 combined	 with	 both	 the	
pDONR221	 vector	 and	 BP	 Clonase	 II	 enzyme.	 This	 enzyme	 carries	 out	 site-
	 49	




of	 1	 µL	 proteinase	 K.	 Positive	 and	 negative	 controls	 were	 included	 with	 the	













determine	 between	 the	 newly	 formed	 construct	 and	 the	 entry	 clones.	 The	
destination	vector	encoded	for	an	ampicillin	resistance	gene,	whereas	the	entry	
clone	encoded	 for	kanamycin	resistance.	Therefore	 the	new	construct	could	be	






All	 RNA	 constructs	 used	 in	 this	 study	 were	 purchased	 from	 TriLink	
































The	 RNA	 gels	 used	 in	 this	 study	were	 all	 3%	 agarose	 (w/v)	 in	 TBE	 buffer.	 As	







The	 gel	 was	 removed	 from	 the	 solution	 and	 transferred	 into	 a	 gel	 dock	 for	
imaging	 (Molecular	 Imager	 Gel	 Doc	 XR+,	 BioRad,	 USA).	 The	 images	 were	






Cells	 used	 in	 this	 study	 were	 originally	 obtained	 from	 a	 long-term	 storage	 in	
liquid	nitrogen.	The	freezing	media	was	removed	by	centrifuging	at	1000	rpm	for	
5	minutes	 in	 a	 Centra-3C	 centrifuge	 (International	 Equipment	 Company,	USA),	






ensure	 the	 cell	 line	were	 not	 affected	 by	 the	 freeze	 thaw	 a	 series	 of	 passages	
were	performed.	Each	passage	involved	the	removal	of	old	media,	washing	in	5	
mL	PBS,	 detaching	 the	 cells	 using	 2	mL	0.05%	Trypsin-EDTA	 for	 7	minutes	 at	
37°C,	spinning	down	at	1000rpm	for	4	minutes	and	resuspension	in	at	least	5	mL	
DMEM.	 From	 the	 5	mL	 of	 resuspended	 cells	 an	 average	 of	 a	 1/5	 dilution	was	
carried	out	before	addition	of	10	mL	of	DMEM	 in	a	T-75	 (200	mL)	cell	 culture	
flask.	This	process	was	carried	out	a	minimum	of	twice	before	the	use	of	the	cell	
line	experimentally	and	a	maximum	of	10	times	before	a	new	aliquot	was	thawed	







To	 establish	 correct	 storage	 of	 the	 cells,	 first	 they	 were	 grown	 to	 80-90%	
confluency,	washed	 in	 2	mL	 of	 PBS-EDTA,	 before	 addition	 of	 1	mL	 of	 trypsin-

















designed	 constructs	 for	 the	 bicistronic	 fluorescence	 assay.	 The	 transfection	
reagent	used	was	Lipofectamine	2000,	at	a	ratio	of	5	parts	Lipofectamine	2000	
(μL)	 to	 1	 part	DNA	 (μg).	 500	ng	 of	 each	DNA	plasmid	was	 diluted	 in	 45	 μL	 of	
serum-free	 DMEM	 before	 the	 introduction	 of	 2.5	 μL	 of	 Lipofectamine	 2000	
diluted	 in	47.5	μL	of	serum-free	media	and	 incubated	at	room	temperature	 for	
20	minutes.	During	this	time	the	cells	were	trypsinised	and	resuspended	in	5	mL	
DMEM	prior	 to	 counting	a	10	μL	 sample,	which	was	 stained	with	Trypan	blue.	








Transfected	 cells	 were	 harvested	 using	 100	 μL	 Passive	 Lysis	 Buffer	 (Promega	
Corporation,	 USA).	 The	 media	 present	 in	 the	 wells	 was	 removed	 via	 suction,	







96	 non-treated,	 sterile,	 black	 polystyrene	 plate	 to	 minimize	 auto-fluorescence	
and	internal	reflection.	The	plate	was	then	read	by	the	POLARstar	Optima	(BMG	
Labtech,	Germany).	To	detect	the	green	fluorescent	protein	(eGFP)	the	filter	was	
set	 at	 485	 nm	 excitation	 and	 520-P	 emission	 and	 for	 detection	 of	 the	 red	
fluorescent	 protein	 (tdT)	 the	 filter	 setting	was	 544	 nm	 excitation	 and	 590	 nm	
emission.	The	position	delay	was	set	to	1.0	seconds	and	30	flashes	per	well.	To	













The	outputted	numbers	 are	 in	 relative	 fluorescence	units	 (RFU).	To	determine	
the	efficiency	of	 the	 frameshifting	regions	 the	data	must	be	normalised	against	
control/background	level	noise.	It	is	then	calculated	against	a	positive	control,	in	
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the	 cast	 of	 these	 systems	 a	 readthrough	 (RT)	 construct,	 using	 the	 equation	

















Class	 II	 type	 A2,	 Esco,	 Micro	 Pte	 Ltd.	 Singapore)	 or	 a	 fume	 hood	 (Xtracare,	
Thermoplastic	Engineering	Ltd.	New	Zealand).	All	pipette	tips	used	were	sterile,	








The	 compounds	 were	 stored	 in	 a	 -20	 freezer	 and	 removed	 from	 this	













There	 are	 significant	 differences	 between	 the	 in	 vivo	 frameshift	 efficiencies	 of	
HIV-1	 (5-10%)	 and	 PEG10	 (60-65%).	 One	 or	 more	 of	 the	 motifs	 within	 the	
element:	slippery	sequence,	intercodon,	or	secondary	structural	component,	are	
inferred	to	make	specific	contributions	that	result	in	the	observed	efficiencies	of	




“slipperiness”	 of	 its	 UUUUUUA	 slippery	 sequence,	 and	 that	 the	 easier	 this	
sequence	can	slip	back	 in	 the	ribosomal	decoding	centre	and	 then	re-pair	with	
two	tRNAs,	the	higher	the	efficiency.	This	second	re-pairing	is	most	likely	due	to	





This	 diagram	 shows	 the	 slippery	 sequence	 and	 intercodon	 of	 HIV-1	 (left)	 and	 PEG10	 (right).	
Black	lines	and	three	letter	codes	indicate	the	tRNAs	that	bind	to	each	of	the	nucleotide	triplets	in	
the	zero	frame.	Red	lines	and	codes	are	when	a	-1	frameshift	has	occurred.	Purely	from	an	amino	

































the	 full	 element	 constructs	 by	 interchanging	 the	 sub-elements	 between	 the	
constructs.	 Each	of	 these	 constructs	was	 then	 cloned	 into	 the	bicistronic	 assay	
system,	 developed	 by	 Tony	 Cardno	 of	 the	 Tate	 research	 group	 (Cardno	 et	 al.	
2009).	The	system	much	like	a	dual	luciferase	assay	has	two	fluorescent	proteins	
separated	by	the	gene	or	segment	of	interest.	In	this	case,	the	segment	of	interest	
is	 a	 native	 or	 hybrid	 frameshift	 element	 flanked	 by	 an	 enhanced	 green	













intercodon,	 and	 the	 third	 is	 the	 secondary	 structural	 element.	 RT	 denotes	 the	 read-through,	






As	 the	 native	 constructs	 had	 already	 been	 produced	 within	 the	 group	 and	
inserted	into	the	bicistronic	fluorescence	assay	plasmid	in	by	previous	students	
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(Cardno,	 2009;	 Hampton,	 2010),	 the	 simplest	 way	 to	 create	 the	 sub-element	




























Liu	 and	 Naismith	 paper	 (2008).	 The	 key	 to	 the	 procedure	 is	 a	 difference	 in	
annealing	 temperatures	 between	 overlapping	 and	 non-overlapping	 regions	 of	
















region	 is	 ~10°C	 higher	 to	 ensure	 that	 the	 overlapping	 region	 anneals	 first.	 In	 this	 system	 the	
substitution	 region	 occurs	 immediately	 after	 the	 overlapping	 region	 to	 ensure	 that	 binding	 of	
that	region	occurs	early	in	the	PCR	cycle.		The	lower	sequence	data	is	taken	directly	from	the	HPH	
sequence	 used	 in	 the	 experimental	 procedure,	 with	 the	 substitution	 region,	 being	 the	 PEG10	
intercodon	in	place	of	the	HIV-1	sub-element.	
	
The	 sub-element	 constructs	 were	 produced	 via	 PCR	 protocol	 and	 due	 to	 the	
relatively	 small	 changes	 in	 size,	 it	was	determined	 that	 any	 successful	 changes	
would	not	be	able	to	be	visualized	easily	simply	by	gel	electrophoresis.	For	this	
reason,	 the	 construct	 containing	 the	 PCR	 product	 was	 transformed	 into	
competent	 cells	 and	 amplified	 by	 incubating	 overnight.	 The	 subsequent	 DNA,	
extracted	 via	 a	 Maxi	 Kit	 (Qiagen,	 Germany),	 was	 sent	 for	 sequencing	 to	
determine	if	the	mutations	had	been	successfully	introduced,	as	shown	in	Figure	
3.4.	Sequencing	was	also	carried	out	in	the	reverse	direction	through	the	green	
fluorescence	 region	 and	 ensured	 that	 non-sense	 mutations	 had	 not	 been	







































specific	 primers	 used	 to	 anneal	 the	 plasmid	 containing	 the	 native	 construct.	 Red	 triangles	
indicate	 the	mutation	 to	 be	 introduced	 into	 the	 sequence.	 Black	 bars	 indicate	 the	 native	 (un-




All	 constructs	 were	 aligned	 to	 known	 sequences	 via	 the	 basic	 local	 alignment	
search	 tool	 (Altschul,	 1990).	 The	 major	 region	 of	 interest	 was	 the	 secondary	
structural	 elements	of	 the	 constructs,	 as	 the	 slippery	 sequence	 and	 intercodon	
where	short	enough	to	check	manually.	Every	SSE	matched	a	reference	genome	
in	the	database	other	than	the	“R	base”	in	PEG10.	
The	 read	 depths	 observed	 in	 the	 sequencing	 add	 confidence	 that	 the	 inserted	
mutations	are	present	 in	 the	vast	majority	of	 the	DNA	 in	 the	 sample.	This	was	
expected,	as	the	dpnI	digest	will	have	removed	any	methylated	parental	DNA.	If	
there	were	significant	contamination,	the	base	calling	would	have	misreads	and	
general	 background	 noise.	 However,	 the	 “R	 base”	 seen	 in	 any	 construct	
containing	the	PEG10	secondary	structural	element,	 is	 thought	 to	be	caused	by	
the	area	of	high	adenine	density	in	the	sequence	directly	adjoining,	the	guanine	
































The	 bicistronic	 assay	 system	was	 first	 developed	by	 Cardno	 et	al.	 (2009),	 as	 a	
replacement	 for	 the	more	 variable	 but	more	 sensitive	 dual	 luciferase	 reporter	
assay	 system.	 The	 beauty	 of	 its	 design	 is	 in	 its	 simplicity;	 while	 the	 dual	
luciferase	system	relies	on	the	oxidation	of	 luciferin	via	 the	 luciferase	enzymes	
produced	 by	 the	 specific	 constructs	 (Mathew,	 2008).	 The	 bicistronic	 system	
requires	no	added	substrates.	With	the	fluorescent	proteins	being	present	after	
expression	 in	 the	cell	 lysate,	when	an	excitatory	wavelength	of	 light	 is	given	to	
the	 sample	 the	 fluorescence	of	 each	 reporter	 can	be	measured	directly	using	a	





with	 the	 top	bar	 indicating	 the	 first	 open	 reading	 frame	 (ORF1)	 in	 the	0	 frame.	The	offset	 bar	
shows	 the	 second	ORF	 in	 the	 -1	 frame.	The	middle	 (white)	 region	 in	both	 the	 top	 and	bottom	
constructs	 signifies	 the	 frameshift	 region.	 The	 bottom	 construct	 shows	 the	 outline	 of	 the	
bicistronic	fluorescence	assay	construct,	with	eGFP	in	the	0	frame	and	tdT	in	the	-1	frame.	
	
The	 constructs	 used	 for	 this	 bicistronic	 assay	 utilize	 two	 fluorescent	 proteins,	





















two	 reporters.	 Therefore	when	 the	 sub-element	 constructs	 are	 expressed	 in	 a	













data	 is	 much	 tighter	 in	 both	 systems,	 indicating	 that	 the	 higher	 concentration	 will	 give	 more	
reproducible	and	consistent	results.	The	volumes	shown	are	the	amounts	of	reagent	added	per	
































Frameshift Efficiency in Varying 































Frameshift Efficiency in Varying




Although	 fluorescence	 values	were	 suitable	with	 both	 concentrations,	 2.5μL	 of	




previous	 results	 frameshift	 experiments	 (Cardno	 et	al.	 2009;	 Hampton,	 2010).	
HEK293T	 cells	 were	 the	 cell	 line	 of	 choice	 due	 to	 their	 robustness	 when	
transfected	 and	 their	 higher	 frameshift	 efficiency	 compared	 to	 Cos-7	 cells	









Native	 elements	 were	 used	 in	 each	 experiment	 to	 act	 as	 a	 positive	 control,	
meaning	 that	data	between	experiments	 could	be	normalized	 for	 comparisons.	
Nevertheless	 the	 native	 control	 data	 needed	 to	 be	 both	 reproducible	 and	





















Comparison of HIV-1 and PEG10 Native Constructs
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overall	 (mean	 of	 5.252%)	was	 just	within	 the	 expected	 5-10%	 (Cardno,	 2007;	
Mathew,	 2008),	 however	 bifluorescent	 reporters	 tend	 to	 give	 somewhat	 lower	
values	than	the	dual	luciferase	reporters	(Cardno	et	al.	2009).	There	is	some	day-
to-day	variation	of	expression	among	unique	biological	replicates.	The	efficiency	





There	 are	 two	 schools	 of	 thought	 on	 how	 PRF	 efficiency	 varies	 between	
organisms.	 The	 first	 is	 that	 the	 slippery	 sequence	 is	 dominant.	 This	 was	
concluded	 by	 Horsfield	 et	 al.	 (1995),	 from	 the	 results	 where	 the	 secondary	
structural	component	was	removed	and	frameshifting	still	occurred.	It	suggested	
that	a	long	ribosomal	pause	at	the	element	mediated	by	the	secondary	structure	
may	not	be	as	 important	 to	a	high	 frameshift	efficiency	as	 the	“slipperiness”	of	
the	 sequence.	 However,	 if	 it	 were	 as	 simple	 as	 this,	 the	 efficiency	 of	 PEG10	
should	have	been	lower	than	that	of	HIV-1,	because	UUUUUUA	can	re-pair	with	
two	tRNAs	on	shifting	than	the	GGGAAAC	seen	in	PEG10	which	can	re-pair	with	
only	one	 tRNA.	PEG10	however	 shows	efficiency	 roughly	3-fold	higher	 in	vitro	







would	 therefore	be	 logical	 to	presume	 the	HPP	construct	will	have	 the	highest	












WT	 HIV-1,	 PPP	 WT	 PEG10;	 the	 two	 sub-element	 constructs	 have	 had	 the	 slippery	 sequence	
mutated	to	express	the	sequence	of	the	other.	Substitution	of	the	HIV-1	slippery	sequence	with	
that	 of	 PEG10	 shows	 a	 significant	 drop	 in	 the	mean	 frameshift	 efficiency	 (5.252%	 to	0.897%),	
this	 is	 expected,	 as	 the	 sequence	 is	 much	 less	 slippery	 in	 the	 PEG10	 system.	 However,	 the	
substitution	of	the	HIV-1	sequence	for	the	PEG10	did	not	increase	the	mean	frameshift	efficiency	
as	 expected,	 it	 decreased	 from	 20.39%	 to	 11.57%,	 indicating	 that	 there	 may	 be	 a	 degree	 of	







defined.	The	 intercodon	has	a	high	degree	of	 conservation	 in	all	HIV-1	 isolates	
and,	 although	 it	 had	 not	 been	 included	 in	 most	 proposed	 mechanisms	 of	
frameshifting,	 the	 importance	 to	 the	 function	 of	 the	 element	 has	 now	 been	
documented	 (Mathew	et	al.	 2015).	Mathew	et	al.	 showed	 the	 intercodon	 could	
influence	 frameshifting	 efficiency.	 By	mutating	 the	 intercodon	 but	 also	 adding	
compensating	mutations	to	maintain	the	two	base	pairs	at	the	base	of	the	stem-
loop	 secondary	 structural	 component,	 they	 showed	 the	 specific	 codon	 in	 the	
intercodon	position	could	change	markedly	frameshift	efficiency.	The	intercodon	






























possible	 importance	 of	 the	 subelement	 to	 the	 frameshift	 efficiency.	 This	 figure	 shows	 that	
mutation	of	the	wobble	base	(last	letter)	significantly	decreases	the	frameshift	element	(seen	by	
the	decrease	in	GGA).	To	prove	that	this	decrease	was	not	caused	by	a	decrease	in	the	size	of	the	
stemloop,	 they	 mutated	 the	 final	 two	 base	 pairs	 in	 the	 steploop	 (GGG_AA),	 but	 this	 mutation	
caused	 a	 smaller	 decrease	 than	 GGA,	 showing	 the	 effects	were	 likely	 due	 to	 the	 effects	 of	 the	
intercodon,	 rather	 than	 the	 decreased	 size	 of	 the	 stemloop.	 This	 is	 further	 validified	 via	 the	
subsiquent	 mutations	 used	 in	 which	 they	 mutated	 the	 intercodon	 to	 a	 greater	 extent	 (UGA	
series).	 No	 significant	 difference	 between	 the	 UGA	 and	 UGA_U	 can	 be	 seen,	 therefore	 any	
mutation	 of	 the	 intercodon	 shows	 a	 negative	 effect	 on	 frameshift	 efficiency,	 regardless	 of	 the	
changes	 in	 the	 stemloop	 structure.	 This	 is	 further	 proven	 by	 the	 UAG	 construct	 which	 was	
designed	 to	 have	 a	 stronger	 binding	 A-U	 pairing	 at	 the	 base	 of	 the	 stemloop.	 It’s	 low	
frameshifting	efficiency	shows	that	the	mutation	of	 the	 intercodon	itself	 is	more	detrimental	 to	





HIV-1	 element	 and	 a	 significant	 site	 of	 frameshifting	was	 after	 the	 intercodon	
had	 been	 decoded.	 This	 was	 determined	 from	 Mass	 spectrometry	 analysis	 of	
frameshift	 peptides.	 The	 PEG10	 intercodon	 is	 not	 part	 of	 the	 pseudo	 knot	
secondary	 structural	 component	 in	 the	 PEG10	 element.	 As	 there	 may	 be	 less	









The	 substitution	of	 the	HIV-1	 (GGG)	 intercodon	 to	 the	PEG10	 intercodon	 (TCC)	 caused	a	 small	
but	significant	increase	in	the	mean	frameshift	efficiency	(5.252%	to	7.166%).	This	indicates	that	
there	 is	an	effect	on	 the	overall	 frameshift	 efficiency	caused	by	 the	 intercodon	 in	HIV-1.	 In	 the	
contrary	to	this	result	when	the	opposite	substitution	was	carried	out,	no	significant	variation	in	
mean	 frameshift	 efficiency	 was	 observed	 indicating	 that	 any	 activity	 from	 the	 intercodon	 in	
PEG10	 is	 minimal	 (20.39%	 to	 20.49%).	 Frameshift	 efficiency	 was	 calculated	 by	 normalizing	




Substituting	 the	 highly	 conserved	 GGG	 intercodon	 in	 the	HIV-1	 construct	with	
the	 TCC	 of	 PEG10	 significantly	 increased	 frameshift	 efficiency	 by	 ~1%	
(proportionally	~20%),	 probably	 to	 add	 to	 that	 fraction	 of	 the	 ribosomes	 that	
slip	after	decoding	the	intercodon	in	the	native	element.		By	contrast,	swapping	
the	intercodon	in	the	PEG10	frameshift	element	with	that	of	HIV-1	did	not	create	
a	 significant	 difference	 to	 the	 frameshift	 efficiency	 (Figure	 3.10).	 Cardno	 et	al.	
(2015)	 found	 almost	 all	 frameshifting	 occurred	 before	 the	 intercodon	 in	 the	
PEG10	element	was	reached,	in	contrast	to	that	of	HIV-1.	As	well	the	distance	of	
the	 intercodon	 to	 the	 secondary	 structure	 is	 greater	 than	 that	 for	 HIV-1.	
Therefore,	 for	these	reasons	the	intercodon-ribosome	interaction	is	 likely	to	be	
much	smaller	than	that	for	HIV-1.		


























Using	 RNAstructure	 (Reuter	 &	 Mathes,	 2010)	 the	 possible	 secondary	 structure	 of	 the	 RNA	
sequence	was	 predicted.	 A.	 shows	 the	most	 probable	 predicted	RNA	 structure,	 a	 large	 AAGAT	
bulge	 can	 be	 seen	 at	 the	 base	 of	 the	 stemloop,	which	 could	 cause	 a	 stronger	 hindrance	 to	 the	
ribosome.	B.	again	shows	a	 large	bulge	at	 the	base	of	 the	stemloop,	 this	bulge	 is	 likely	to	cause	
further	slowing	of	the	ribosome	therefore	increasing	the	frameshift	efficiency.	C	is	the	least	likely	
iteration	of	the	three	predicted	structures;	the	binding	of	the	slippery	sequence	is	likely	once	the	
rest	of	 the	upstream	sequence	 is	considered.	As	with	all	RNA	predictions	there	 is	no	guarantee	





1	 frameshift	 element,	 it	 is	 important	 to	 examine	 how	 the	 secondary	 structure	
might	have	been	affected	by	the	mutation.	An	RNA	structure	prediction	tool	was	
used	 to	 predict	 three	 possible	 structures	 (Figure	 3.11).	 Figure	 4.9A	 shows	 the	
possible	binding	of	the	TCC	to	a	downstream	GGA,	changing	the	size	and	shape	of	
the	 stem-loop.	 Although	 this	 makes	 the	 stem-loop	 shorter,	 the	 newly	 formed	
AAGAT	 bulge	 may	 cause	 an	 increased	 hindrance	 to	 the	 ribosome	 during	
translation,	 causing	 a	 longer	 pause	 and	 increased	 frameshift	 efficiency.	 4.9B	
seems	less	likely	as	the	shorter	stem-loop	has	been	shown	to	modestly	decrease	
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seems	 to	 be	 the	 least	 likely	 of	 the	 predicted	 secondary	 structures	 as	 the	
likelihood	of	 the	slippery	sequence	binding	any	upstream	sequence	 is	unlikely,	
especially	when	the	full	construct	is	considered.	At	full	length	the	construct	is	not	





The	 secondary	 structural	 element	was	 predicted	 to	 be	 the	major	 contributory	
factor	 to	 the	 high	 frameshift	 efficiency	 seen	 in	 human	 PEG10,	 with	 other	
mammalian	 homologues	 appearing	 to	 have	 a	 lower	 efficiency	 due	 to	
polymorphisms	 not	 present	 in	 human	 copies	 of	 the	 gene	 (Clark	 et	 al.	 2007).		
More	 evidence	 for	 this	 is	 the	 size	 difference	 and	 complexity	 of	 structure	 seen	
between	 the	 HIV-1	 stem-loop	 and	 PEG10	 pseudoknot.	 To	 test	 this	 theory,	 the	




I	 hypothesized	 the	 PEG10	 pseudoknot	 would	 cause	 an	 increase	 in	 frameshift	
efficiency	in	the	HHP	hybrid	element,	and	the	HIV-1	step	loop	a	decrease	in	the	
PPH	hybrid	element.	Indeed	there	was	an	observed	decrease	from	21%	to	1%	in	
frameshift	 efficiency	 (proportionally	 95%)	 in	 the	 PPH	 element,	 indicating	 how	
important	the	pseudoknot	is	to	the	PEG	frameshift	efficiency	(Figure	3.12).	This	
is	a	highly	significant	result	as,	in	addition	to	the	data	for	PHH,	it	shows	that	the	











result	 as	 the	 drop	 in	 efficiency	 was	 much	 higher	 than	 expected.	 	 Frameshift	 efficiency	 as	
calculated	by	normalizing	against	a	read-through	and	a	control.	HHH	denotes	WT	HIV-1,	PPP	WT	
PEG10,	the	two	sub-element	constructs	have	had	the	slippery	sequence	and	intercodon	mutated	
to	 express	 the	 sequence	of	 the	other.	 ****	=	P≤0.0001	 calculated	with	 students	unpaired	 t-test	
(n=12)	SEM	values	represented	by	error	bars.	
	
Consistent	 with	 this	 result,	 addition	 of	 the	 PEG10	 pseudo	 knot	 to	 the	 HIV-1	
construct	in	place	of	the	stem	loop	produced	a	2-fold	higher	frameshift	efficiency	
(4-8%)	 than	 that	 of	 the	 native	 HHH	 construct.	 This	 is	 expected,	 as	 the	 larger	
complex	secondary	structure	will	likely	slow	the	ribosome	more	effectively	than	
the	 small	 stem-loop	while	 it	 is	being	unwound,	 therefore	 increasing	 frameshift	
efficiency.	 However	 this	 finding	 is	 interesting	 also	 if	 the	 distance	 between	 the	
slippery	sequence	and	the	secondary	structure	in	the	published	RNA	structures	
is	taken	into	account	(Clark	et	al.	2007).	Although	the	pseudoknot	is	larger	than	
the	 stem-loop	 and	 therefore	 should	 increase	 the	 frameshift	 efficiency,	 the	
increase	 is	 quite	 substantial	 and	 may	 relate	 to	 an	 underlying	 distance	 based	
hypothesis.	By	 this	 it	 is	meant	 that	 for	 the	 frameshift	 to	occur	at	 a	 rate	higher	
than	 seen	 in	 HIV-1	 there	 is	 a	 “Goldilocks	 Zone”,	 the	 perfect	 distance	 of	 the	



































construct	 (5.252%,	 8.573%	 and	 11.57%,	 respectively).	 This	 indicates	 that	 the	 conserved	
sequence	in	the	HIV-1	-1PRF	region	may	not	be	fine	tuned	to	maximum	levels	of	 frameshifting,	
but	 tailored	 to	 the	 specific	 efficiency	 needed	 by	 the	 virus	 to	 accurately	 produce	 live	 virus.	
Frameshift	 efficiency	 as	 calculated	 by	 normalizing	 against	 a	 read-through	 and	 a	 control.	 HHH	
denotes	 WT	 HIV-1,	 the	 two	 sub-element	 constructs	 have	 had	 the	 slippery	 sequence	 and	
intercodon	 interchanged	 to	 express	 the	 specific	 sequence	 of	 the	 PEG10	 sub-elements.	 ****	 =	
P≤0.0001	calculated	with	students	unpaired	t-test	(n=12)	SEM	values	represented	by	error	bars.	
	
There	 is	a	 significant	 increase	 in	 frameshifting	with	 the	presence	of	 the	PEG10	
intercodon,	 indicating	 that	 the	 pairing	 of	 the	 pseudoknot	 with	 its	 own	 TCC	
intercodon	is	important.	As	has	been	found	in	Mathew	et	al.	2015	the	HIV-1	GGG	




































The	 underlying	 hypothesis	 found	 from	 the	 observed	 data,	 is	 that	 HIV-1	 relies	
heavily	 on	 the	 slippery	 sequence	 for	 the	 5-7%	 frameshift	 efficiency,	 however	
PEG10	 efficiency	 is	 almost	 entirely	 controlled	 by	 the	 secondary	 structural	
element.	The	intercodon	has	a	more	subtle	but	important	role	within	in	each	of	
the	elements.	The	minor	increase	seen	in	the	HPH	construct	shows	that	as	GGG	is	
highly	 conserved	 between	 HIV-1	 strains,	 it	 may	 be	 fine	 tuning	 a	 specific	










The	 functional	 analysis	 experiments	 described	 in	 the	 previous	 results	 chapter	
contributed	 to	 the	 central	 focus	 of	 the	HIV-1	 research	 carried	 out	 in	Tate	 Lab,	
drug	 development.	 This	 chapter	 focuses	 on	 the	 binding	 of	 the	 previously	
discovered	 stimulators	 of	 programmed	 ribosomal	 frameshifting	 in	 HIV-1	
(Cardno	 et	 al.	 2015).	 The	 major	 hindrance	 to	 the	 development	 of	 drug	
compounds	is	drug	specificity,	however	the	previous	study	did	not	show	where	
within	the	frameshift	element	the	drug	compounds	were	binding	or	how	specific	
they	 were	 to	 HIV-1.	 Without	 this	 knowledge	 the	 development	 of	 any	 drug	
compound	is	not	 likely	to	go	 into	the	next	phase	of	drug	development.	For	this	
reason	 experiments	 to	 find	where	 on	HIV-1	 the	 compounds	were	 binding	 and	






(Hammell	 et	al.),	 however	 the	 confirmation	 of	 the	 frameshifting	 activity	 of	 the	
gene	in	human	cell	lines	was	only	shown	in	2014	(Belew	et	al.).	It	is	therefore	the	
least	studied	of	the	-1	frameshifting	regions	in	the	human	genome,	meaning	that	
only	 very	 small	 amounts	 of	 information	 on	 how	 frameshifting	 occurs	 in	 this	
region	and	even	less	is	understood	on	possible	effects	of	drug	compounds	on	the	
region.	As	the	CCR5	-1PRF	region	is	a	much	longer	sequence	than	in	HIV-1	and	









using	 the	 Gateway	 Recombination	 Cloning	 Technology	 system	 (Thermo	 Fisher	







resulting	PCR	product	then	had	attB	sequences	annealed	to	the	ends	to	prepare	 it	 for	 insertion	
into	 the	DONR221	 vector,	 via	 the	BP	Clonase	 reaction.	 The	 native	DONR221	 vector	 contains	 a	
ccdB	suicide	vector,	so	if	the	CCR5	construct	does	not	insert	the	transformed	cell	will	die.	During	
the	 LR	 Clonase	 reaction	 the	 product	 from	 the	 BP	 Clonase	 reaction	 then	 is	 inserted	 into	 the	
destination	vector,	containing	the	bicistronic	fluorescence	assay.	The	lower	boxes	in	the	vectors	










Add BP Clonase II and DONR221
Add LR Clonase II and Destination Vector
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After	transformation	of	the	full	length	CCR5	construct	supplied	by	Origene	(USA)	
into	DH5α	cells,	 the	DNA	was	extracted	and	site	 specific	primers	were	used	 to	
amplify	the	-1	programmed	ribosomal	frameshift	region	of	the	construct.	A	DpnI	
digest	was	used	 to	destroy	any	of	 the	methylated,	 template	DNA.	The	resulting	
DNA	was	run	on	an	agarose	gel	and	showed	DNA	present	at	 the	correct	 length	
(not	 shown).	 Another	 PCR	 reaction	 was	 carried	 out,	 where	 attB	 regions	 were	





Shows	 the	 successful	 amplification	 and	 presumed	
mutation	of	the	CCR5	constructs.	The	marker	used,	100bp	
DNA	 ladder	 (NEB,	 USA).	 -1PRF	 region	 amplification	 PCR	





the	 ends	was	 also	 successful	 as	 can	 be	 seen	 in	 the	 other	 two	 bands	 at	 200bp	





Sequence	data	 showing	 the	CCR5NAT	and	CCR5RT	 constructs	 and	 the	 sub	 elements	 contained	
within	 them.	 The	 two	 constructs	 have	 identical	 intercodon	 and	 secondary	 structural	 element	
sequence,	however	due	 to	 the	extra	base	 in	 the	CCR5RT	slippery	 sequence	 region,	 the	 reading	
frame	is	in	the	-1,	causing	the	construct	to	act	as	if	a	frameshift	event	had	occurred.	The	slippery	
sequence	has	also	been	mutated	 from	TTTAAAA	 to	TTTCCTAA,	 the	 same	sequence	used	 in	 the	























letters	 indicate	 the	 bases	 of	 the	 attB	 regions.	 Blue	 shows	 the	 C	 inserted	 to	 ensure	 the	 correct	





without	 the	 addition	 of	DMSO	or	 drug	 compounds	 to	 ensure	 they	 gave	 results	
consistent	with	the	frameshift	efficiencies	seen	in	Belew	et	al.	2014	(Figure	4.6).	
These	 values	 fell	 in	 the	 range	 of	 values	 given	 by	 Belew,	 however	 the	 CCR5	
construct	 appeared	 to	 behave	 differently	 to	 the	 PEG10	 and	 HIV-1	 derived	
constructs.	With	 fluorescence	values	often	 close	 to	 the	baseline	 control	 values,	
and	 variability	 of	 red	 fluorescence	 levels,	 it	 was	 presumed	 that	 the	 construct	
might	have	picked	up	a	mutation	during	DNA	synthesis	or	extraction.	However	
after	 analysis	 of	 sequence	 data	 and	 a	 several	 extra	 rounds	 of	 transfection	
procedure	 the	 fault	 was	 thought	 to	 be	 due	 to	 an	 interaction	 between	 the	
construct	 and	 the	 cell	 line.	 	 Further	 testing	 on	 the	 viability	 of	 transfecting	 the	
construct	into	different	cell	lines	would	prove	interesting	and	might	be	an	insight	
into	 the	 reasoning	 behind	 three	 different	 cell	 lines	 being	 used	 in	 the	 Belew	





Prior	 to	 the	 following	 experimental	 results,	 the	 binding	 positions	 of	 the	 three	
compounds	found	to	have	modulatory	effects	on	the	frameshift	efficiency	in	HIV-
1	were	unknown	(Cardno	et	al.	2015).	However	the	leading	view	from	the	Tate	
Lab	 (in	which	 the	paper’s	experimental	procedures	were	carried	out)	was	 that	




the	 ribosome,	 leading	 to	 the	 idea	 that	 by	 the	 small	 molecule	 binding	 to	 the	
stemloop	 the	 ribosome	 will	 be	 slowed	 for	 a	 longer	 period	 and	 frameshift	
efficiency	 will	 increase.	 Once	 this	 increase	 has	 occurred	 it	 is	 hoped	 that	 the	
imbalance	 in	 the	 volumes	 of	 protein	 produced	will	 throw	 the	 system	 out	 and	
cause	the	HIV-1	to	greatly	reduce	its	infectivity.	
Although	 in	 the	 2015	 paper	 the	 greatest	 increase	 in	 efficiency	 was	 shown	 in	
compound	A2,	due	to	the	apparent	negative	effects	seen	in	PEG10,	compound	A3	
was	selected	 for	 the	study	of	 the	binding	positions	 in	 the	 three	native	and	 two	
sub-elemental	constructs,	by	reason	of	 the	minimal	effects	seen	on	PEG10.	The	
inference	 that	 none	 of	 the	 compounds	 actually	 produced	 a	 high	 enough	 fold-
change	 in	 frameshift	 efficiency	 needed	 for	 a	 significant	 decrease	 in	 viral	





Cardno	and	Shimaki’s	work	 into	 the	development	of	 small	molecule	 frameshift	
modulators	 proved	 three	 compounds	 had	 effect	 on	 the	 frameshift	 efficiency	 of	




the	experiments	 carried	out	 in	 this	 thesis.	Due	 to	 the	drug	 compounds’	known	
modulatory	effects	on	HIV-1,	binding	is	known	to	occur	at	one	or	possibly	more	
sites	 of	 the	 HIV-1	 -1PRF	 region.	 Three	 biotinylated	 constructs	 based	 from	 the	
HIV-1	slippery	sequence,	 intercodon	and	stemloop	were	obtained	 from	TriLink	
Biotechnologies	 (USA)	 for	 the	 putative	 binding	 analysis	 (Figure	 4.4).	 The	
constructs	are	named	after	the	sub-elements	which	they	contain.	Note	that	due	
to	its	close	proximity	to	the	slippery	sequence	and	its	presence	in	the	stem-loop	
secondary	 structure,	 the	 intercodon	 has	 been	 included	 in	 each	 of	 these	
constructs.	For	this	reason,	if	binding	is	seen	in	all	of	the	constructs	it	will	give	an	
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indication	 of	 binding	 to	 the	 intercodon,	 although	 this	 is	 unlikely	 as	 small	




























However	 in	 the	 case	 of	 the	 IC-SS	 (intercodon-SSE	 construct)	 and	 ss-IC-SS	 (full	
length	construct),	with	addition	of	compound	A2,	 the	RNA	constructs	appeared	
	 79	
to	 have	 completely	 disappeared	 from	 the	 gel.	 If	 the	 compound	 being	 were	
contaminated	 with	 RNases	 and	 the	 RNA	 had	 completely	 degraded	 during	 the	
incubation	 step	 a	 smearing	 of	multiple	 size	 RNA,	 all	 smaller	 than	 the	 starting	
material,	 would	 be	 expected.	 The	 disappearance	 of	 the	 RNA	 fragments	 could	











(NEB,	 USA).	 HIV-1	 ss-IC	 with	 compound	 A2	 (lane	 1),	
HIV-1	 ss-IC	 (lane	 2),	 HIV-1	 IC-SS	 with	 compound	 A2	
(lane	3),	HIV-1	IC-SS	(lane	4),	HIV-1	ss-IC-SS	with	compound	A2	(lane	5),	HIV-1	ss-IC-SS	(lane	6).	
Control	 lanes	 had	 the	 same	 volume	 of	 DMSO	 (50%	 total	 volume)	 added	 as	 the	 lanes	 with	










be	 seen	 on	 the	 gel,	 the	 lanes	 with	 tRNA	 and	 compound	 added	 still	 have	 the	
presence	of	 the	 intact	 tRNA	band	at	 the	 same	position	of	 those	untreated	with	
compound	A2.	This	suggests	that	the	compound	does	not	contain	RNases,	as	they	
would	have	 caused	 the	 tRNA	 to	 form	smaller	products	 as	 they	were	degraded.	
This	 is	 further	 validated	when	 comparing	 the	 lanes,	which	had	 the	 addition	of	
tRNA	pre	and	post	 incubation,	presence	of	RNase,	would	cause	 the	 intensity	of	














of	 the	 IC-SS	 samples	 in	 these	 lanes	 is	 now	 thought	 to	 be	 due	 to	 a	 large	 RNA-
compound	complex	 that	does	not	 leave	 the	wells.	These	complexes	were	again	






HIV-1	 IC-SS	 with	 compound	 A2	 (lane	 1),	 HIV-1	 IC-SS	
(lane	 2),	 HIV-1	 IC-SS	 with	 addition	 of	 tRNA	 prior	 to	
incubation	with	compound	(lane	3),	HIV-1	IC-SS	with	addition	of	t-RNA	prior	to	incubation	(lane	
4),	HIV-1	 IC-SS	with	addition	of	 tRNA	post-incubation	with	compound	A2	(lane	5),	HIV-1	 IC-SS	
with	addition	of	tRNA	post-incubation	with	(lane	6),	Control	lanes	had	the	same	volume	of	DMSO	




unexpected,	 there	 is	 a	 high	 probability	 that	 the	 activity	 seen	 was	 caused	 by	
compound	 A2	 binding	 to	 the	 secondary	 structure	 of	 IC-SS	 and	 ss-IC-SS.	 From	
these	results	it	was	determined	that	due	to	the	unexpected	putative	interaction	





Due	 to	 the	 formation	 of	 RNA-compound	 complexes	 seen	 in	 the	 optimization	
work	with	compound	A2,	it	was	assumed	that	compound	A3	would	behave	in	the	




compound	A3.	However	when	visualized	on	 an	 agarose	 gel,	 the	 compound	did	
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the	RNA.	The	decrease	of	intensity,	in	comparison	to	the	disappearance	of	bands	
with	 compound	 A2,	 could	 suggest	why	 compound	 A3	 has	 a	 lower	 affinity	 and	
thereby	 a	 lower	 modulatory	 effect	 than	 A2	 in	 previous	 tissue	 culture	
experiments.	 If	 the	 binding	 specificity	 is	 lower	 in	 compound	 A2	 than	 in	 A3	
(which	 is	apparent	by	 its	effects	on	PEG10	frameshifting),	 then	 it	could	bind	to	
the	 secondary	 structural	 element	 more	 often	 and	 stronger	 than	 seen	 in	
compound	A3.		
The	ss-IC	bands	appear	to	have	the	same	intensity	across	the	three	treatments,	
indicating	 that	 no	 binding	 has	 occurred	 between	 compound	 A3	 and	 the	 RNA	
construct.	 This	 is	 to	 be	 expected,	 as	 compound	 A3	 is	 thought	 to	 have	 a	 high	




varying	 condition	 of	 heat	 treatment	 to	 denature	 the	 RNA,	 therefore	 stopping	 binding	 of	 the	
compound	 to	any	 secondary	 structural	 element	present	 in	 the	 samples.	The	marker	used,	Low	
Range	ssRNA	Ladder	(NEB,	USA).	HIV-1	ss-IC	untreated	(lane	1),	HIV-1	ss-IC	with	compound	A3	
heat-treated	 (lane	 2),	 HIV-1	 ss-IC	with	 compound	A3	 (lane	 3),	 HIV-1	 IC-SS	 untreated	 (lane	 4),	
HIV-1	 IC-SS	with	 compound	A3	heat-treated	 (lane	5),	HIV-1	 IC-SS	with	 compound	A3	 (lane	6),	
HIV-1	ss-IC-SS	untreated	(lane	7),	HIV-1	ss-IC-SS	with	compound	A3	heat-treated	(lane	8),	HIV-1	





Contrary	 to	 the	 expected	 outcomes	 for	 the	 heat-treated	 RNA	with	 addition	 of	
compound	A3,	 the	 bands	 showed	 a	 similar	 intensity	 as	 those	 treated	with	 the	
compound	without	 heat	 denaturation	 of	 the	 RNA.	 This	 could	 indicate	 that	 the	
binding	 of	 the	 compound	 has	 already	 occurred	 and	 binds	 tightly	 enough	 that	
heat-treatment	 is	 not	 enough	 to	 remove	 the	 compound	 and	denature	 the	RNA	
secondary	 structure.	 Another	 hypothesis	 is	 that	 all	 the	 RNA	 constructs	 are	
denatured	 by	 the	 high	 concentration	 of	 DMSO	 in	 the	 compound	 and	 therefore	
control	lanes.	For	adequate	drug	compound	to	be	present	in	the	sample,	the	total	
DMSO	percentage	in	each	lane	was	50%.	High	concentrations	of	DMSO	have	been	
































reason,	 various	 concentrations	 of	 DMSO	were	 tested	 with	 the	 RNA	 constructs	
and	compound	to	ensure	that	the	RNA	was	in	a	secondary	structure	allowing	the	
compound	to	bind	(Figure	4.8).	Those	lanes	treated	with	2%	and	10%	compound	
A3	 show	 a	 decrease	 in	 intensity	 of	 the	 bands	 in	 comparison	 to	 the	 controls.	
There	 appears	 to	 be	 a	 greater	 difference	 in	 intensity	 than	 seen	with	 the	 50%	
DMSO	concentration	 lanes	 in	 the	previous	 figure.	This	 indicates	 that	 the	DMSO	
could	 have	 been	 denaturing	 the	 majority	 of	 the	 RNA	 and	 therefore	 inhibiting	
binding	 of	 the	 compound.	 	 At	 these	 lower	 concentrations,	 even	 though	 the	
concentration	of	compound	A3	is	lower,	the	amount	of	RNA	available	to	bind	is	
higher.	This	hypothesis	is	only	applicable	for	compound	A3,	as	it	is	thought	that	










with	 loading	 dye	 (lane	 9),	 ss-IC-SS	with	 2%	DMSO	 (lane	 10),	 ss-IC-SS	with	 2%	 compound	 A3	
(lane	11),	ss-IC-SS	with	10%	compound	A3	(lane	12),	ladder	made	as	per	recommended	by	NEB	
(M2).	Control	 lanes	had	 the	 same	volume	of	DMSO	 (2%	 total	 volume)	added	as	 the	 lanes	with	































bands	 is	 unlikely	 to	 be	 caused	 by	 a	mobility	 shift,	 as	 compound	 A3	 has	 a	 low	
molecular	weight	in	comparison	to	the	weight	of	any	of	the	RNA	molecules.		Even	
at	 3%,	 the	 agarose	 gel	 did	 not	 separate	 the	 fragments	 sufficiently	 to	 show	 a	
difference	 between	 native	 RNA	 bands	 and	 RNA	 that	 have	 been	 treated	 with	
compound	A3.	 An	 increase	 of	 agarose	 percentage	was	 unlikely	 to	 increase	 the	
definition	of	the	bands	enough	to	separate	the	treated	and	untreated	bands.		
As	each	of	 the	gels	 showed	enough	definition	 to	confirm	some	 form	of	binding	
action,	 it	was	decided	to	carry	on	with	binding	experiments	in	human	cell	 lines	





Mobility	 shift	 assays	 implied	 the	 small	molecule	modulatory	 compounds	were	
binding	to	the	secondary	structures	of	HIV-1	but	little	is	known	whether	this	is	
the	mechanism	when	 tested	within	 a	 eukaryotic	 system.	 This	 is	 still	 the	most	
likely	 mechanism	 by	 which	 modulation	 occurs,	 as	 binding	 to	 the	 secondary	
structure	would	 slow	 the	 ribosome	 over	 the	 slippery	 sequence	 (Brierley	 et	al.	
2010).	 An	 alternative	 mechanism,	 in	 which	 the	 compound	 binds	 the	 slippery	
sequence	 or	 intercodon	 is	 unlikely,	 as	 frameshifting	 occurs	 when	 these	 two	
elements	 are	 present	 in	 the	 ribosome	 (Mathew	 et	 al.	 2014).	 A	 small	molecule	

















The	 effects	 on	 the	 frameshift	 efficiency	 of	 CCR5	 in	 the	 presence	 of	 any	 of	 the	
compounds	 previously	 tested	 by	 Cardno	 (2015)	 had	 not	 been	 evaluated	
previously.	With	compound	A3,	it	can	be	seen	that	any	effects	are	barely	over	the	
minus	A3	control,	and	significantly	 lower	 than	 the	 level	needed	 to	significantly	
negatively	effect	CCR5	protein	expression.	This	may	be	due	to	the	complexity	of	
the	secondary	structural	element,	thought	to	be	the	binding	site	for	each	of	the	













validate	 the	 hypothesis	 an	 ex	 vivo	 experimental	 procedure	 would	 have	 to	 be	
used,	 as	 external	 factors	 present	 in	 the	 cellular	 environment	 could	 affect	 the	
binding	properties	(Tyrell	et	al,	2013).		
As	 the	 compound	 was	 presumed	 to	 bind	 to	 the	 secondary	 structure,	 using	
constructs	 where	 the	 HIV-1	 secondary	 structure	 and	 intercodon	 had	 been	
substituted	 for	 the	PEG10	sequence,	would	allow	us	 to	 see	whether	binding	of	
the	 compound	occurred	 in	 the	 secondary	 structural	 element	or	 in	 the	 slippery	
sequence.	 If	 the	HPP	 construct	 behaved	 like	 the	 PEG10	 native	 construct	when	
exposed	to	compound	A3,	the	binding	must	occur	in	the	secondary	structure,	as	
without	the	HIV-1	stemloop	the	effects	of	the	compound	is	lost.	However,	if	the	





The	modulatory	 effects	 on	HHH	 and	HPP	when	 exposed	 to	 0-20μM	 compound	 A3.	 Frameshift	






The	 HIV-1	 construct	 showed	 a	 1.7-fold	 increase	 in	 frameshift	 efficiency	 when	













the	 same	 effect	 needed	 to	 be	 shown	 in	 a	 construct	 containing	 this	 secondary	




nature	 of	 the	 HIV-1	 construct.	 Two	 of	 the	 guanine	 bases	 that	 make	 up	 the	
intercodon	are	also	the	first	two	binding	bases	in	the	stemloop,	meaning	that	if	

















although	 much	 higher	 than	 seen	 in	 the	 HHH	 construct,	 indicates	 that	 both	
binding	 has	 occurred	 in	 the	 secondary	 structure	 and	 perhaps	 that	 with	 some	
tweaks	 to	 the	 small	molecule,	 the	 ideal	 goal	 of	 a	 3-fold	 increase	 in	 frameshift	
efficiency	 thought	 to	 be	 required	 to	 inhibit	 infectivity	 in	 the	 HIV-1	 system.	
Nevertheless,	 the	 efficiency	 of	 the	 PHH	 construct	 is	 only	 approximately	 1%,	
much	 lower	 than	 any	 of	 the	 other	 constructs	 tested,	meaning	 that	 the	~3	 fold	
change	was	still	a	relatively	small	percentage	increase.	When	the	HHH	construct	
was	 tested	 the	 1.7-fold	 increase	 could	 account	 meant	 an	 overall	 ~17.3	 %	
frameshift	 efficiency.	 This	 effect	 shows	 the	 importance	 of	 relating	 the	 change	




obvious	 modulatory	 activity	 caused	 by	 the	 addition	 of	 compound	 A3.	 This,	 in	
combination	with	 the	HIV-1	 results	 in	 Figure	 4.10,	means	 it	 can	 be	 concluded	





the	 modulatory	 effects	 have	 occurred	 in	 the	 constructs	 containing	 the	 HIV-1	





Throughout	 the	experimental	work	 carried	out	 in	 this	 study,	development	 and	
expression	 of	 the	 CCR5	 constructs	 proved	 difficult.	 There	 were	 fluctuating	
results	 caused	 by	 day-to-day	 variation	 in	 expression	 of	 fluorescent	 markers	
when	 transfected	 into	 HEK293T	 cells	 (Appendix	 III).	 The	 addition	 of	 DMSO,	
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transfection	reagents	and	compound	A3,	appeared	to	have	caused	a	detrimental	




one	 of	 the	 fluorescent	 reporters.	 A	 small	 trend	 of	 an	 increase	 of	 frameshift	





Frameshift	 efficiency	as	 calculated	by	normalizing	against	 a	 read-through	and	a	 control.	 (n=12	
for	 all	 other	 than	 5μM,	which	 has	 n=11,	 biological	 replicates	 taken	 over	 3	 separate	 days,	 in	 8	
replicates	 Lipofectamine2000	 was	 used,	 the	 subsequent	 4	 were	 carried	 out	 using	
XtremeGENEHP)	 SEM	 values	 represented	 by	 error	 bars.	 Those	 values	 without	 stars	 are	 not	
significant.	
	
It	 is	 unknown	 how	 detrimental	 the	 effects	 of	 this	 small	 an	 increase	 would	
actually	be	to	the	host	as	mutations	in	CCR5,	such	as	delta-32	often	have	positive	
effects	 by	 mutating	 the	 receptor’s	 ability	 to	 bind	 potentially	 hazardous	
pathogens.	The	standard	deviation	of	 the	1.2-fold	 increase	was	0.26,	 indicating	
that	 the	margin	 for	error	 could	be	high	enough	 for	 the	 increase	 to	be	down	 to	
chance.	It	is	therefore	most	likely	that	like	PEG10,	compound	A3	does	not	bind	to	
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In	 conclusion,	 this	 study	 gives	 definitive	 evidence	 that	 the	 hypothesis	 of	 the	
small	 modulatory	 compounds	 binding	 to	 the	 secondary	 structural	 element	 of	
HIV-1	 is	 the	most	mode	 of	 action.	 The	 RNA	 gels	 suggested	 indirectly	 bonding	
activity	in	RNA	containing	the	stemloop.	This	was	then	validated	by	the	increase	
of	 frameshift	 efficiency	 in	 both	 the	 constructs	 containing	 the	 HIV-1	 secondary	
structural	 element	 and	 by	 contrast	 no	 change	 in	 the	 constructs	 missing	 this	












For	 a	 virus	 like	 HIV-1	 a	 minimal	 genome	 is	 key.	 During	 integration	 a	 smaller	
genome	 will	 insert	 into	 the	 host	 genome	 with	 greater	 ease	 (Itaya,	 1999)	 and	
when	 packaging	 the	 virion	 a	 reduced	 genome	will	 be	 accommodated	within	 a	
smaller	and	easier	to	produce	nucleocapsid	(Ilie	et	al.	2006).	HIV	has	decreased	
its	genome	size	by	utilising	overlapping	genes,	with	a	mechanism	that	can	switch	




how	 the	 individual	 parts	 of	 the	 element	 contribute	 to	 the	 observed	 frameshift	
efficiencies	in	HIV-1	but	also	a	human	gene	PEG10	that	uses	this	mechanism.	And	
(ii)	 how	 an	 isolated	 modulatory	 compound	 derived	 from	 high	 throughput	
screening	of	a	114	000	chemical	library	(Cardno	et	al.	2015)	mediates	it	effect	on	
frameshift	 efficiency.	 Although	 studies	 have	 suggested	 the	 importance	 of	 both	
the	 heptameric	 slippery	 sequence	 and	 the	 three	 nucleotide	 intercodon	 that	
follows	it	 in	regards	to	conservation	among	subtypes,	few	experimental	studies	
have	 given	 strong	 conclusions	 as	 to	 the	 exact	 function	 of	 each	 of	 the	 sub-














possible	 to	 develop	 drugs	 against	 the	 HIV-1	 viral	 element	 that	 will	 not	 affect	
PEG10	 expression,	 or	 against	 PEG10	 specifically.	 This	 might	 be	 important,	 as	





Classical	 analysis	 of	 the	 HIV-1	 frameshifting	 mechanism	 indicated	 that	 a	 25	
nucleotide	 sequence	 downstream	 from	 the	 slippery	 sequence	was	 sufficient	 to	
produce	 an	 efficiency	 close	 to	 that	 of	 the	 native	 element	 (Wilson	 et	al.	 1988),	
suggesting	 the	 slippery	 sequence	was	 the	major	 determinant	 of	 the	 efficiency.	
My	 study	 showed	 the	 substitution	 of	 the	HIV-1	 slippery	 sequence	with	 that	 of	
PEG10	 (PHH	 in	 Figure	 3.8),	 decreased	 the	 frameshifting	 efficiency	 by	
approximately	 83%.	 	 This	 finding	 is	 consistent	with	mutational	 studies	 on	 the	
HIV-1	 slippery	 sequence,	 in	 which	 any	 mutation	 of	 the	 slippery	 sequence	
(including	those	conforming	to	the	XXXYYYZ	motif)	caused	a	marked	decrease	in	
frameshift	 efficiency	 (Biswas	 et	 al.	 2004).	 Thus	 the	 slippery	 sequence	 is	
important	 for	 the	 observed	 efficiency	 in	 HIV-1	 in	 vivo;	 consequently	 the	
intercodon	 and	 secondary	 structural	 element	 may	 just	 act	 as	 additives	 to	 the	
slippery	sequence	base	efficiency.		
In	contrast,	PEG10	is	thought	to	be	heavily	reliant	on	its	secondary	structure	to	
produce	 its	 much	 higher	 frameshifting	 efficiency	 (Lux	 et	 al.	 2005).	 If	 this	
hypothesis	 is	 correct,	 the	 substitution	 of	 the	 “more	 slippery”	 HIV-1	 slippery	
sequence	 should	 increase	 the	 frameshifting	 efficiency.	 However	 instead	 of	 an	
increase,	 the	 addition	 of	 the	HIV-1	 sub-element	 (HPP	 in	 Figure	 3.8)	 decreased	
the	 PEG10	 efficiency	 to	 approximately	 57%	 of	 the	 native	 construct.	 This	 is	 a	
surprising	 result	 when	 compared	 with	 the	 decrease	 observed	 in	 PHH;	 if	 one	
construct	 decreases	 the	 frameshifting	 efficiency	 surely	 the	 inverse	 mutation	
would	cause	an	 increase	 in	efficiency.	The	solution	 to	 this	may	be	 found	 in	 the	





on	 its	 large	 secondary	 structural	 element	 and	 therefore	 there	 is	 a	 degree	 of	
specificity	to	create	the	observed	frameshifting	efficiency.	Mutational	analysis	on	
Edr	 (PEG10	 orthologue),	 showed	 a	 larger	decrease	 of	 frameshifted	products	 in	





When	analysing	 the	slippery	sequence	and	 intercodon	of	 the	HIV-1	and	PEG10	
programmed	ribosomal	 frameshift	regions	 it	becomes	apparent	 that	re-binding	
of	the	anticodon	to	the	intercodon	after	the	event	of	frameshifting	appears	to	be	
difficult	(Figure	3.1).	In	the	case	of	HIV-1	the	anticodon	would	be	specific	to	the	
GGG	 intercodon	 (CCC),	 but	 after	 the	 event	 takes	 place	 this	 CCC	would	 need	 to	
bind	 AGG,	 leaving	 an	 A:C	mismatch	 in	 the	 first	 position.	 	 However	 due	 to	 the	
three	hydrogen	bonds	present	between	both	G:C	pairings	the	intercodon	binding	
would	 be	 of	 similar	 strength	 to	 the	 binding	 of	 a	 triple	 A:U	 codon-anticodon	
interaction	 (both	 six	bonds	 each).	Thus	 the	mismatch	of	 the	 first	position	may	
not	 be	 as	 detrimental	 as	 first	 thought,	 allowing	 late	 frameshifting	 to	 occur	
(where	 the	 frameshift	 occurs	 at	 the	 intercodon	 site).	 In	 contrast	 the	 native	
PEG10	 sequence	 shows	 a	UCC	 intercodon,	which	would	 cause	 the	 recruitment	
and	binding	of	a	GGA	anticodon.	When	the	 frameshifting	event	has	 taken	place	




unfavourable	 in	 this	 position.	 With	 an	 unfavourable	 first	 and	 second	 codon	
binding	positions,	late	frameshifting	would	be	unlikely	in	PEG10	as	re-pairing	of	








seen	 when	 the	 HIV-1	 intercodon	 was	 mutated	 to	 for	 a	 stop	 codon	 and	
frameshifting	efficiency	decreased	(Mathew	et	al.	2015).	However	in	the	case	of	
HPH,	 the	 addition	 of	 the	 PEG10	 intercodon	 increased	 the	 efficiency	 by	





intercodon	was	 substituted	 into	 PEG10	 there	was	 no	 significant	 change	 in	 the	
frameshifting	 efficiency	 observed	 (PHP,	 Figure	 3.10).	 This	 indicates	 that	 the	 0	
frame	 intercodon	 is	 not	 sampled	 before	 the	 frameshifting	 event.	 However	 an	
approximately	 75%	 decrease	 in	 efficiency	 was	 observed	 when	 the	 intercodon	








overall	 frameshifting	efficiency	 in	 -1PRF	(Giedroc	&	Cornish,	2009).	Due	 to	 the	
relatively	 unfavourable	 re-pairing	 of	 the	 slippery	 sequence	 and	 intercodon	 in	
PEG10,	 it	 is	 thought	 that	 the	 large	SSE	 facilitates	a	 long	pause	that	 leads	to	 the	
vast	majority	of	observed	frameshifting	efficiency.	Substitution	of	the	PEG10	SSE	
with	 that	 of	 HIV-1	 showed	 a	 huge	 decrease	 in	 the	 frameshifting	 efficiency	 of	
approximately	95%	of	the	original	value	(PPH,	Figure	3.12).	Thus	indicating	that	
the	 smaller	 HIV-1	 stem-loop	 cannot	 sufficiently	 slow	 the	 ribosome	 enough	 to	
allow	frameshifting	to	occur	at	a	high	rate.	This	leads	me	to	believe	that	PEG10	
has	an	all	or	nothing	frameshifting	mechanism;	without	the	strong	hindrance	of	





The	strong	presence	of	 the	PEG10	pseudoknot	 is	proven	when	 it	 is	substituted	
for	the	HIV-1	stem-loop.	The	construct	HHP	showed	a	highly	significant	increase	
of	 approximately	 60%	 in	 frameshifting	 (Figure	 3.12).	 The	 increase	 is	 probably	




is	not	always	better;	HIV-1	does	not	 require	 the	high	efficiency	seen	 in	PEG10,	
because	 it	would	cause	a	protein	 imbalance	and	the	high	 infectivity	rate	would	
be	lost.		
One	large	difference	in	the	possible	interactions	in	HIV-1	and	PEG10	between	the	




tension	 is	 required	 for	 the	 breaking	 of	 the	 codon-anticodon	 bonds	 and	 the	





caused	 by	 size	 disparity	 in	 their	 SSEs,	 leads	 to	 the	 question	 of	 how	 CCR5	 can	
have	 such	 low	 frameshifting	 efficiency	with	 such	 a	 large	proposed	pseudoknot	
and	 an	 incredibly	 similar	 slippery	 sequence	 to	 HIV-1?	 Belew	 et	 al.	 (2014)	
showed	that	for	the	CCR5	frameshifting	element	to	function	correctly,	it	relies	on	
micro	RNAs	 (miRNAs)	 to	 control	 the	mechanism.	When	added	 in	excess	 to	 the	













The	 exact	 mechanism	 by	 which	 frameshifting	 occurs	 is	 still	 unknown,	 with	
several	 possible	 and	 current	 hypotheses	 (Brierley	 et	 al.	 2010).	 However	 the	
results	of	intercodon	interaction	in	HIV-1	may	shed	new	light	onto	which	of	the	
hypotheses	 are	most	 plausible.	 The	differences	 seen	between	 the	native	HIV-1	
construct	 and	 HPH	 indicate	 that	 the	 intercodon	 is	 sampled	 prior	 to	 the	
frameshifting	 event,	 which	 would	 place	 the	 intercodon	 in	 the	 A	 site	 of	 the	
ribosome.	However	 for	 this	 to	 occur	 the	 first	 three	 nucleotides	 of	 the	 slippery	
sequence	 would	 need	 to	 be	 present	 in	 the	 E	 site.	 This	 result	 implies	 that	 no	
hypothesis,	which	places	 the	 first	 three	nucleotides	of	 the	slippery	sequence	 in	
the	P	site	as	an	essential	at	the	time	of	the	frameshifting	event,	can	be	accurate.	




intercodon	 to	be	 in	 the	 ribosomal	 tRNA	docking	 sites	during	 the	 frameshifting	
event.	This	is	further	validated	when	the	results	shown	by	Cardno	et	al.	(2015)	
are	 taken	 into	 account.	 Using	 mass	 spectrometry	 they	 developed	 the	 idea	 of	
early,	 middle	 and	 late	 frameshifting	 products,	 where	 peptides	 were	 shown	 to	
contain	-1	frameshifted	sequence	beginning	at	each	of	the	three	possible	codons	






of	 action?	 The	 sequence	 has	 had	 time	 to	 mutate	 from	 that	 of	 its	 probable	
ancestral	element	allowing	a	possible	variation	 in	 the	mechanism	(Clarke	et	al.	
2007).	 Perhaps	 the	 elements	 derived	 from	 human	 genes	 now	 use	 a	 different	
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mechanism	 from	 those	 of	 viral	 origin,	 in	 the	 case	 of	 mammalian	 derived	






Previously	 Cardno	 et	 al.	 (2015)	 discovered	 three	modulatory	 compounds	 that	




compounds	 and	 CCR5.	When	 transfected	 into	HEK293T	 cells	 and	 treated	with	
the	 compound,	 CCR5	 showed	 no	 aberration	 from	 the	 untreated	 samples,	
indicating	 no	 interaction	 between	 it	 and	 the	 small	 compounds.	 Due	 to	 the	
complexity	 of	 the	 CCR5	 pseudoknot	 and	 the	 observed	 specificity	 of	 the	 small	
modulatory	compound	 to	HIV-1,	 it	was	not	unexpected	 that	 the	 compound	did	
not	 bind.	 Despite	 this,	 if	 the	 compound	 had	 shown	 some	 effect	 on	 the	













The	overwhelming	hypothesis	 for	 the	binding	position	of	 the	three	modulatory	






assays	 and	 mobility	 shift	 assays	 using	 agarose	 gel,	 I	 was	 able	 to	 show	 the	
putative	evidence	of	compound	A2	and	A3	to	the	SSE	of	HIV-1	(Figures	4.5,	4.6	&	
4.10).	Firstly	the	mobility	shift	assays	indicated	that	the	compound	was	binding	
to	 the	 full	 length	 and	 SSE	 constructs,	 however	 not	 in	 the	 expected	 traditional	
shifting	pattern,	instead	showing	fainter	band	of	RNA	or	complete	disappearance	
of	 the	 RNA	 band	 completely.	 While	 his	 effect	 could	 have	 been	 caused	 by	
degradation	of	the	RNA	by	RNase	contamination	in	the	compounds,	however	no	
activity	 was	 observed	 on	 tRNAs	 added	 to	 the	 loading	 mix.	 Alternatively	 the	








and	 SSE	 were	 present,	 so	 why	 not	 use	 constructs	 where	 only	 the	 SSE	 was	
substituted?	The	answer	lies	within	the	HIV-1	sequence,	as	the	intercodon	makes	
up	 the	 first	 two	 nucleotides	 of	 the	 secondary	 structure,	 which	 implicates	 that	
binding	 of	 the	 compound	 could	 be	 partly	 to	 the	 intercodon.	 Due	 to	 the	
conclusions	drawn	from	the	intercodon	substitution	studies,	there	is	interaction	
between	 the	 ribosome	 and	 intercodon,	 potentially	 in	 the	 A	 site	 (Mathew	 et	al.	
2015).	This	means	that	 if	any	 interaction	between	the	 intercodon	and	the	drug	
compound	was	to	occur	it	would	have	to	detach	prior	to	the	intercodon’s	entry	
into	the	ribosome,	which	would	relieve	the	tension	on	the	system	and	would	no	









As	with	any	potential	drug	 compound	 in	development,	 the	 compounds	used	 in	
this	 study,	 or	 those	 based	 from	 them,	 will	 have	 to	 undergo	 clinical	 studies	 to	
ensure	there	are	no	adverse	affects	related	to	the	drug.	Due	to	the	nature	of	the	
compounds	 used	 (small	 molecule,	 RNA	 binding),	 there	 is	 a	 distinct	 possibility	
that	off	target	binding	could	occur.	If	binding	to	another	secondary	structure	in	
the	host	occurred,	there	may	be	issues	with	the	translation	of	that	specific	region	
of	 mRNA.	 Binding	 of	 the	 small	 molecule,	 if	 strong,	 could	 potentially	 cause	
ribosomal	drop	off,	due	to	lengthened	stoppages.	However	due	to	the	nature	of	
compound	A3’s	 observed	 off-target	 activity,	 or	 lack	 of	 it,	 it	 is	 thought	 that	 the	
chances	 of	 off-site	 binding	 are	 minimal.	 The	 concept	 of	 small	 molecule	
compounds	 selectively	 binding	 target	 RNA	 has	 existed	 for	 years	 but	 has	 only	
been	 recently	 shown	 to	 occur.	 Yang	 et	 al.	 (2016)	 developed	 a	 small	 molecule	
compound	 that	 binds	 specifically	 to	 a	 r(AUUCU)	 repeat	 associated	 with	 the	
condition	 spinocerebellar	 ataxia	 10.	 Although	 the	 mechanism	 of	 action	 is	
different	 to	 this	potential	 treatment	of	HIV-1,	 the	study	shows	how	specifically	
the	small	molecule	can	bind	 their	 region	of	 interest,	 reporting	 the	monomer	of	
the	compound	a	40-fold	higher	binding	affinity	than	control	GC	RNA.	
The	 use	 of	 databases	 such	 as	 SMMRNA	 (small	 molecule	 modulators	 of	 RNA	
[Mehta	 et	 al.	 2014])	 could	 potentially	 be	 used	 to	 compare	 the	 small	 molecule	
modulators	 and	 RNA	 sequence	 in	 this	 study	 with	 others	 used,	 to	 determine	
where	 possible	 interactions	may	 occur.	 Although	 any	 possibility	 of	 interaction	
seems	 low	due	 to	specificity	of	 the	compound	on	HIV-1	vs.	PEG10	&	CCR5,	 the	
possibility	of	binding	 to	other	RNA	viruses	 is	possible.	This	adds	potential	 that	
the	compounds	discovered	could	be	used	as	a	broad-spectrum	anti-viral	or	anti-
retroviral.	 However,	 although	 the	 blueprint	 for	 the	 frameshifting	 region	 is	
conserved	 across	 all	 frameshifting	 elements,	 the	 secondary	 structural	 element	
proximal	 to	 the	 slippery	 sequence	 and	 the	 number	 of	 bases	 between	 the	 two	
sub-elements	 are	 not	 conserved	 across	 retroviridae	 (Atkins	 et	 al.	 2016).	








the	 targeting	 frameshifting	 as	 a	 treatment	 of	 HIV-1	 is	 the	 virally	 derived	
mammalian	 frameshifting	 regions,	 such	 as	 PEG10.	 Normally	 the	 expression	 of	
PEG10	 is	 relatively	 low	 within	 humans,	 with	 very	 little	 of	 the	 frameshifted	
product	 present	 within	 samples	 analysed	 (Shimaki,	 2015).	 However	 ten	 days	
post-conception	 in	 mice	 PEG10	 appears	 in	 the	 placenta,	 with	 frameshifted	
product	observed.	Studies	show	that	with	knockout	of	the	complete	PEG10	gene,	






exclude	 the	 risk	 of	 pregnancy	 and	 thus	 avoiding	 miscarriage.	 In	 the	 case	 of	




carried	 out	 on	 a	 larger	 scale.	 With	 the	 average	 drug	 development	 process	







1PRF	 region	 has	 raised	 several	 questions	 as	 to	why	 there	 is	 such	 disparity	 in	
each	of	 the	known	frameshifting	efficiencies.	One	such	example	 is,	whether	 the	
PEG10	 slippery	 sequence	 and	 intercodon	 can	 cause	 the	 ribosome	 to	 slip	 back	
without	 the	 presence	 of	 its	 large	 SSE	 or	 whether	 they	 even	 add	 increased	







Little	 is	 known	 about	 which	 of	 the	 CCR5	 sub-elements	 causes	 the	 observed	
frameshifting	 efficiency.	 Belew	 et	 al.	 (2014)	 showed	 that	 overexpression	 of	
miRNAs	could	strengthen	the	secondary	structure	and	increase	efficiency.	Is	the	
SSE	 strong	 enough	 to	 cause	 the	 observed	 efficiency	 alone,	 and	 with	 a	 similar	
efficiency	 to	 HIV-1,	 would	 swapping	 the	 two	 SSEs	 significantly	 change	 the	
efficiency?		
In	 the	 case	 of	 PEG10	 and	 CCR5,	 potential	 RNA-Compound	 interaction	 further	
evidence	of	minimal	binding	may	be	 required	as	 the	methods	used	 in	vitro	 are	
not	as	precise	as	those	used	ex	vivo.	To	confirm	that	no	binding	occurs	and	that	it	
does	 in	 HIV-1,	 surface	 plasmon	 resonance	 could	 be	 employed.	 By	 binding	 the	
small	molecule	 compound	 to	 the	gold	 substrate	and	passing	 the	RNA	of	 choice	
over	 the	 bound	 molecule	 could	 prove	 an	 interaction	 between	 RNA	 and	 the	
compound,	 as	 once	 bound	 the	 absorption	 of	 light	 would	 increase	 due	 to	 the	
increased	mass	of	the	molecule.	
Many	 drug	 compounds	 require	 improvement	 from	 the	 initial	 testing	 phase,	 as	
the	 desired	 effect	 of	 the	 compounds	 is	 not	 sufficient	 to	 effectively	 lower	
infectivity.	 Compound	 A3	 is	 no	 different,	 as	 it	 is	 thought	 to	 effectively	 lower	
infectivity	in	HIV-1	an	increase	of	at	least	3-fold	is	required	(Nikolić	et	al.	2012).	
Therefore	 small	 alterations	 to	 the	 molecule	 or	 delivery	 system	 would	 be	




in	 the	 drug	 development	 process	 is	 in	vivo	 studies.	 I	would	 suggest	 the	 use	 of	








In	 conclusion	 these	 studies	 have	 shown	 insight	 into	 the	 sequence	 specific	
ribosomal	interactions	and	the	effects	of	addition	of	modulatory	compounds	on	
these	 interactions.	 The	 effects	 of	 sub-elements	 within	 the	 -1PRF	 region	 vary	
between	 organisms,	 with	 each	 of	 the	 HIV-1	 sub-elements	 contributing	 to	 the	
final	frameshifting	efficiency,	whereas	PEG10’s	secondary	structural	element	has	
an	 all	 or	 nothing	 effect	 on	 the	 system.	 HIV-1	 is	 thought	 to	 be	 sampling	 the	
intercodon	 prior	 to	 frameshifting,	 a	 result	 that	 demands	 a	 review	 on	 the	
accepted	mechanisms	of	 frameshifting.	The	 small	modulatory	 compounds	have	
been	 shown	 to	 bind	 the	 HIV-1	 stem-loop	 and	 thus	 far	 no	 other	 mammalian	




























































































































































































































































































































































































































































































































































































































Construct	 Round	1	 Round	2	 Round	3	 Round	1	 Round	2	 Round	3	
HHH	 0.031915	 0.055039	 0.025213	 0.054673	 0.073695	 0.064385	
	
0.028116	 0.058352	 0.035123	 0.075334	 0.063694	 0.066650	
	
0.032060	 0.059127	 0.032907	 0.058815	 0.064769	 0.063861	
	




	 	 	 	
0.077876	 0.068971	 0.068980	
	 	 	 	
0.081532	 0.068126	 0.075128	
	 	 	 	
0.072764	 0.063094	 0.065489	




























































	 	 	CCR5	 0.072073	 0.065718	 0.062610	 	 	 	
	 0.062959	 0.052638	 0.057373	 	 	 	
	 0.078002	 0.054488	 0.070220	 	 	 	
	 0.061562	 0.053646	 0.051571	 	 	 	
	






Construct	 Conc.	μM	 Round	1	 Round	2		 Round	3	



















































































Construct	 Conc.	μM	 Round	1	 Round	2	 Round	3	
























































































Construct	 Conc.	μM	 Round	1	 Round	2	 Round	3	




























Construct	 Conc.	μM	 Round	1	 Round	2		 Round	3	








































20	 0.036632071	 0.34743523	 0.129998007	
	 	
0.055545575	 0.380769416	 0.11470813	
	 	
0.053037452	 0.388650176	 0.121862513	
	 	
0.038232717	 0.374543611	 0.159212458	
	
CCR5	showed	large	variation	between	days,	however	the	fold-changes	observed	
were	consistent	across	all	concentrations.	
